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Abstract 
Glioblastoma multiforme (GBM) is the most common and most malignant 
primary brain tumour. The prognosis for patients remains poor with a median survival 
time falling well short of a year in spite of surgical removal of tumour followed by 
radiotherapy. GBM is resistant to the current treatment regimen, often due to therapeutic 
resistance, however combination therapies have been proven to have a beneficial effect 
on the prognosis of patients. Aspirin, one of the most commonly used drugs reduces the 
viability and proliferation of glioblastoma both in vitro and in vivo. This study 
examined the combination of aspirin or its analogue PN517 with the standard 
chemotherapeutic (cisplatin) and determined effects on cell viability, apoptosis and 
caspase activity. Either aspirin or PN517 combined with cisplatin significantly reduced 
the viability of U87-MG glioblastoma cells. The apoptosis induced by cisplatin was 
augmented in combination with either PN517 or aspirin. These results for the first time 
suggest a potential for improved treatment of glioblastoma multiforme where aspirin or 
its analogue PN517 are combined with the standard chemotherapeutic drugs cisplatin.  
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1 Introduction  
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1.1 Introduction – Central Nervous System Tumours 
Brain tumours, while rare in comparison to cancers such as breast or prostate, 
represent a significant challenge both in terms of diagnosis and treatment. The UK 
annual incidence rate of brain tumours ranges from 14.8 per 100,000 for males and 14.6 
per 100,000 for females (Cancer Research UK, 2014).  Primary brain tumours are those 
arising within the central nervous system (CNS) and represent 1.6% of all the tumours 
diagnosed, whereas secondary brain tumours, resulting from metastasis of non CNS 
tumours, represent 6% of all tumours detected in the UK (Cancer Research UK, 2014). 
While low grade tumours that are slow growing with well-defined borders can usually 
be removed surgically, their location within the CNS presents challenges due to the risk 
of significant neurological sequelae (Veeravagu et al., 2013). This risk increases with 
high grade tumours that grow rapidly and are highly invasive, but most studies show a 
significant improvement in survival that correlates the extent of tumour resection 
(Hervey-Jumper & Berger, 2014). 
 
The main cause of brain tumours, like several other cancers still remains 
unidentified. However, several risk factors have been established which include 
exposure to radiation, previous incidence of cancer, genetic conditions such as 
neurofibromatosis, and other medical conditions such as AIDS (Reilly, 2010). Age is 
also a major factor as the risk of acquiring the disease increases with age, with the age 
group of 50-70 being the most affected (Eheman et al., 2012). Improvements in 
diagnosis, treatment, and prevention of cancer has resulted in a significant improvement 
in the median survival time for all cancers following diagnosis, from 1 year in 1971-72 
to 5.8 years in 2007, with the biggest increase being in colon cancer, improving from 
0.6 to 10 years (Macmillan, 2012). However, brain tumour survival time in UK has 
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shown little improvement, increasing from 0.3 years in 1971 to 0.5 years in 2007. This 
report emphasises the significant challenges that remain in the diagnosis and treatment 
of brain tumours, and highlights the importance of the development of new treatment 
regimens for brain tumours. 
 
1.2 Classification and Grading of Central Nervous System Tumours  
Classification and grading is used to design individual patient treatment 
protocols and to determine their likely prognosis. Additionally, it creates a system that 
can be accepted worldwide allowing for global clinical trials and epidemiological 
studies (Louis et al., 2007a). In 2007, the World Health Organisation (WHO) ratified a 
new wide-ranging classification of neoplasms affecting the CNS (Louis et al., 2007b). 
The classification of brain tumours is based on the abnormal growth of a specific cell 
type, and grading helps in understanding the extent of malignancy or aggressiveness of 
the tumour, with higher grade corresponding to higher malignancy (Loukopoulos & 
Robinson, 2007). The new WHO system is particularly useful in this regard with only a 
few notable exceptions for example, either all or almost all gemistocytic astrocytomas 
are actually anaplastic and hence named grade III or even IV rather than grade II. The 
WHO classification also provides a corresponding grading system for each type of 
tumour where most named tumours are of a single defined grade. An outline of this 
classification is provided below (Table 1.1). 
 
 
 
 
  
  
 
4 
 
Table 1.1: WHO classification of CNS tumours (adapted from Louis et al., 2007) 
Tumours of Neuroepithelial Tissue 
Astrocytic Tumours Choroid plexus Tumours 
Oligodendroglial Tumours Neuronal & mixed neuronal-glial tumours 
Oligoastrocytic Tumours Tumours of the pineal region 
Ependymal Tumours Embryonal tumours 
Other neuroepithelial tumours  
Tumours of Cranial and Paraspinal Nerves 
Schwannoma Perineuroma 
Neurofibroma Malignant peripheral nerve sheath tumour 
Tumours of the Meninges 
 
 
 
 
 
 
 
 
 
he Meninges 
Tumours of melingothelial cells Primary melanocytic lesions 
Mesenchymal tumours Other neoplasms related to the meninges 
Lymphomas and Haematopoietic Neoplasm 
Malignant lymphomas Granulocytic sarcoma 
Plasmacytoma  
Germ Cell Tumours 
Germinoma Choriocarcinoma 
Embryonal carcinoma Teratoma 
Yolk sac tumour Mixed germ cell tumour 
Tumours of the Sellar Region 
Craniopharyngoma Pituicytoma 
Granular cell tumour Spindle cell oncocytoma 
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Tumour grading plays a very important role in the choice of therapy, especially 
while ascertaining the adjuvant radiotherapy and chemotherapy protocols (NICE, 2006; 
Araujo et al., 2011). The grading of CNS tumours by WHO involves a scheme of 
grading that serves as a malignancy scale (Bratasz et al., 2008). Grade I includes 
tumours that have very low potential to proliferate and higher possibility to cure by 
surgery alone. Grade II tumours are usually infiltrative with low level of proliferation, 
although some grade II tumours may progress to higher malignancy grades. Grade III 
neoplasms have morphological evidence of malignancy such as high mitotic activity 
and nuclear atypical. Lesions designated grade IV are cytologically malignant, necrosis 
prone, involving widespread infiltration of surrounding tissue and a tendency for 
craniospinal dissemination (Louis et al., 2007). WHO grading, in combination with 
several other factors, also aids in predicting the patients response to treatment and in an 
overall prediction of prognosis (Kleihues et al., 2007). 
 
1.3 Glioma 
Primary brain tumours that arise from neuroglial cells, including astrocytes and 
oligodendrocytes, are referred to as glioma (Laws et al., 2003; Nikkhah et al., 1992; 
Fleming et al., 2011). Gliomas are the most common primary tumours of the brain and 
they comprise about 2% of all newly diagnosed cancers every year in the UK (The 
National Institute for Health and Clinical Excellence Cancer Service Guidance, 2007), 
but despite this low incidence, glioma is the leading cause of cancer-related death in 
men aged 20-39 years (Habela et al., 2009).  The incidence of primary brain tumours in 
the UK is similar to that found in the US and with an annual incidence rate of 7 per 
100,000 of the population (McKinney, 2004; Sehmer et al., 2014). To put the incidence 
rate of malignant glioma in perspective, the rate roughly equals that of leukaemia  
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With respect to tumours of the CNS, gliomas account for 40-60% of primary 
brain tumours in adults, of which half are malignant gliomas (Brandes et al., 2008). 
Primary glioblastoma multiforme (GBM) represents approximately 95% of cases, with 
the remaining 5% of cases being secondary GBM typically arising over a period of 
years from either low grade astrocytoma (WHO grade II), or from anaplastic 
astrocytoma (WHO grade III) (Rivera et al., 2008; Jaeckle et al., 2011). Following 
diagnosis, the 5-year survival rate for low grade glioma is 97% following surgical 
resection of greater than 90% of the tumour, but in high grade glioma where the tumour 
is more aggressive and recurrence more common, the median survival is 1-3 years 
(Hervey-Jumper & Berger, 2014).  
 
There are several classes of glioma including astrocytoma, which develop 
anywhere in the brain or spinal cord (Zhou & Mark, 2013). Brain stem gliomas arise in 
the lowest part of the brain, ependymomas develop inside the brain in the lining of the 
ventricles, while oligodendrogliomas usually develop in the cerebrum. This latter form 
is very rare, representing just 3% of all primary brain tumours (Dolecek et al., 2012) 
(Table 1.2). Overall, gliomas are the most common forms of primary brain tumours 
accounting for 80% of all cases (Hervey-Jumper & Berger, 2014).  
 
1.4 Glioma Classification and Grading 
Depending on their cell of origin, gliomas are classified into three main types, 
astrocytoma, oligodendroglioma, and ependymoma (Table 1.2).  
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Table 1.2: WHO classification of Gliomas (Louis et al., 2007).  
Categories in italics are also not recognized by the new WHO classification system, but 
are in common use 
WHO Designation Grade Incidence 
(% of all brain tumours) 
Astrocytic Tumours   
Pilocytic Astrocytoma  
Hemispheric, diencephalic, optic 
I 5-6% 
Diffuse Astrocytoma 
Variants: protoplasmic, fibrillary, mixed 
II 10-15% 
Anaplastic Astrocytoma 
Hemispheric, diencephalic, brain stem, cerebellar 
III 10-15% 
Glioblastoma Multiforme 
Variants: giant cell glioblastoma, gliosarcoma 
IV 12-15% 
Oligodendroglial Tumours   
Oligodendroglioma II 2.5% 
Anaplastic oligodendroglioma III 1.2% 
Ependymal Tumours   
Subependymoma I 0.7% 
Ependymoma II 4.7% 
Anaplastic ependymoma III 1% 
Mixed and other common types of glioma   
Angiocentric glioma I  
Oligoastrocytoma II 1.8% 
Anaplastic oligoastrocytoma III 1.2% 
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Astrocytomas develop from star shaped glial cells called astrocytes found 
throughout the CNS which functions include maintaining extracellular ion levels and 
repairing of tissues (Goodden et al., 2014). They represent the most common type of 
glioma, forming 75% of all cases detected and their occurrence increases with age 
(Berkhard et al., 2003; Dolecek et al., 2012). Astrocytomas are majorly divided into 
two classes; encapsulated and diffuse tumours.  
 
Oligodendrogliomas arise from oligodendrocytes, the cells which form the 
myelin sheath around the axons of nerve cells within the CNS. They can be well 
differentiated oligodendrogliomas which are grade II and have slow growth or 
anaplastic oligodendrogliomas which are of grade III and grow rapidly (Macmillan, 
2014). Oligodendrogliomas form 20% of all tumours of the CNS. They’ve been found 
to be more prevalent in males as compared to females (Dolecek et al., 2012) 
 
Ependymal cells produce and circulate the cerebrospinal fluid, are found lining 
the ventricles and central canal of the spinal cord, and give rise to ependymomas.  They 
are considered to be a rare type of glioma, accounting for 5% of all tumours of the CNS 
(Macmillan, 2014). They include tumours of grade I (myxo-papillary ependydoma and 
sub-ependydoma), II (low grade ependymoma) and III (anaplastic ependymoma) (Louis 
et al., 2007).  
 
The WHO system further grades the tumours on the basis of histological 
degrees of malignancy with Grade I being the least malignant to Grade IV being the 
most malignant (Louis et al., 2007). The degree of malignancy is based on either the 
presence or absence of increased cellularity, nuclear atypia, mitosis, endothelial 
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proliferation and necrosis. Grade I and Grade II tumours are considered to be low grade 
and are usually circumscribed and grow slowly over a period of time while Grade III 
and Grade IV are high-grade tumours and are diffuse and comparatively aggressive 
having poor prognosis (Chandana et al., 2008). 10% of the low-grade gliomas undergo 
malignant transformation to high-grade neoplasms with time and age (Ohgaki & 
Kleihues, 2007). High-grade gliomas are the most common type of brain tumours in the 
adult age group and represent a major cause of morbidity and mortality with a median 
survival time of 12-15 months (Dolecek et al., 2012; Fisher et al., 2010) Glioblastoma 
multiforme (GBM) is the most malignant and aggressive high-grade glioma (WHO 
Grade IV) (Preusser et al., 2011).  
 
1.5 Molecular Markers of Glioma  
Glioma progression is a combined effect of over activation of signalling 
pathways that oversee normal cell growth, abnormal expression by the cellular 
oncogenes and deletion or suppressed activity of tumour suppressor genes (Bernardi et 
al., 2006).  
 
p53 is a tumour suppressor and transcription factor found to be mutated in 50% 
of tumours (England et al., 2013). Activation of p53 is induced by events occurring 
during carcinogenesis which include: genotoxicity, abnormal growth signals, DNA 
damage, hypoxia and loss of cell contacts (Harris, 2005). Various genes upregulated by 
p53 include the ones involved in apoptosis (PUMA, Bax, CD95/Fas, Apaf1), cell cycle 
arrest (p21, 14-3-3autophagy (DRAM, Sestrin 1/2), senescence (PAI-1), 
angiogenesis (TSP1), DNA Repair (R2) and metabolism (PTEN, SCO2) (Harris, 2005). 
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Gliomas often display mutations in the ARF-MDM2-p53 and p16INK4a-CDK4-RB 
tumour suppressor pathways resulting in increased genomic instability, loss of G1 cell 
cycle checkpoint control, and evasion of apoptosis (Hede et al., 2011). 
 
Stat3 is a member of the Stat family of transcription factors which get activated 
via several cytokine and growth factor receptors, normally leading to transient 
phosphorylation of Stat 3 (Bromberg et al., 1999; Darnell et al., 1994; Zammarchi et 
al., 2011). However, in 70% of tumours persistent Stat3 phosphorylation has been 
observed (Zammarchi et al., 2011), initiating transcription of genes promoting anti-
apoptosis, cell cycle-progression, cell survival, migration and invasion (Brantley & 
Benveniste, 2014). Activity of Stat3 is essential to tumour growth and has been noted to 
be of high frequency in gliomas (Luwor et al., 2013). 
 
IDH1 is a member of isocitrate dehydrogenase family found in the cytoplasm 
and aids in catalytic oxidative decarboxylation of isocitrate. Somatic mutations of IDH1 
are found in 70% of high grade gliomas (Lv et al., 2011), and while the wild type 
converts isocitrate to -ketoglutarate (-KG), mutated IDH1 results in formation of D-
2-hydrohygluterate (2-HG). This aids in glioma pathogenesis either via downstream 
effects of 2-HG or by inhibiting isocitrate metabolism (Ohka et al., 2014). 
 
1.6 Astrocytic Tumours 
Astrocytic tumours belong to the neuroepithelial tissue WHO classification and 
are sub-divided into circumscribed (grade I) versus diffuse tumours (grades II-IV) 
(Louis et al., 2007) (Table 1.2). They may also be sub-classified as invasive or non-
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invasive, although this is not formally part of the WHO system. They are the most 
common glioma and occur in most parts of the brain and occasionally the spinal cord; 
however, these tumours rarely metastasise outside the CNS (Habela et al., 2009). There 
are two broad classes of astrocytoma recognized in the literature, the first having narrow 
zones of infiltration that often are clearly outlined on diagnostic images (mostly 
invasive tumours; e.g., pilocytic astrocytoma, subependymal giant cell astrocytoma, 
pleomorphic xanthoastrocytoma), and the second having diffuse zones of infiltration, 
that share various features including the ability to arise at any location in the CNS, but 
with a preference for the cerebral hemispheres (e.g., low-grade astrocytoma, anaplastic 
astrocytoma, glioblastoma) (Srinivasan et al., 2011; Sonabend et al., 2014).   
 
Astrocytomas can develop at any age, however, low-grade is more often found 
in children or young adults, while high-grade is more prevalent in adults (Grier & 
Batchelor, 2006). In children more than 80% of astrocytomas are low grade while 20% 
are high grade (St. Judes Research, 2014). As a proportion of all gliomas detected, low-
grade astrocytomas in adults represent 10% of cases, whereas in children this is 25% 
(Ononiwu et al., 2012).  
 
In adults, grade I astrocytoma are rare and comprise a distinct entity called 
pilocytic astrocytoma which occurs most commonly in the cerebellum in children. 
Grade II astrocytomas account for approximately 10-15% of all astrocytic brain tumours 
with an incidence rate of 1.4 new cases / million people a year (Bigner et al., 1998). 
They affect any region of CNS but predominately occur in the cerebrum followed by the 
brain stem and spinal cord (Wintersperger et al., 2007). Grade II astrocytomas are well 
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differentiated, slow growing and exhibit hyper-cellularity and cellular plemorpheins 
(Louis et al., 2007). 
 
Anaplastic astrocytomas represent 10-15% of all intra-cerebral tumours and 
about 25-30% of all gliomas (Yarbro et al., 2005) (Table 1.2). They generally appear 
between the fourth and fifth decades of life and are more common in males than in 
females (Mohapatra et al., 1998). Grade III astrocytomas show strong mitotic activity 
along with hyper-cellularity and anaplasia, and may be defined as an infiltrating lesion 
with either focal or dispersed anaplasia or marked proliferative potential.   
 
1.7 Grade IV (Glioblastoma Multiforme GBM) 
Glioblastoma multiforme (GBM) is the most common and most malignant 
primary brain tumour accounting for 16% of all diagnosed primary tumours with an 
annual incidence of 2-3 cases per 100,000 (Dolecek et al., 2012; Fisher et al., 2010). 
When the tumour shows either vascular endothelial proliferation and/or the presence of 
necrosis, it is graded as grade IV glioblastoma (Louis et al., 2001; Reiser et al., 2007; 
Chadduck et al., 1991). Regional heterogeneity and highly invasive growth is 
commonly observed, whereas cellular polymorphisms, nuclear atypia, vascular 
thrombosis, may also be observed, albeit not as commonly (Brandes et al., 2008).  
Primary GBM proliferates and spreads to other parts of the brain rapidly and can 
become very large before producing symptoms, which often begin abruptly with 
seizures. Less than 10% are secondary GBM which form more slowly following 
degeneration of low-grade astrocytoma or anaplastic astrocytoma, and are more 
common in younger patients (mean age 45 versus 62 years) (Ohgaki and Kleihues, 
2009). It occurs more commonly in males, 1.6 times more when compared to females 
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(Dolecek et al., 2012). Prognosis remains poor for those with grade IV gliomas with 
few patients surviving beyond 3 years, a median survival time of 17 weeks without 
treatment, 30 weeks with radiation, and 37 weeks with surgical removal of most of the 
tumour followed by radiation therapy. Long term survival (at least five years) falls well 
under 5% in adults, while slightly better at 21% in children (Stupp et al., 2009). 
 
1.8 Diagnosis of Glioma 
Symptoms of glioma depend on the area of the brain affected. The most 
commonly observed symptoms are headaches, seizures, memory loss, physical 
weakness, cognitive decline, and loss of muscle control. Symptoms can exacerbate as 
the tumour progresses (Fox et al., 2007). In the first stage of diagnosis a history of 
symptoms is recorded followed by a basic neurological exam, including an eye exam 
and tests of vision, balance, coordination and mental status (Taylor, 2010). Diagnosis is 
confirmed using either a computerized tomography (CT) scan or magnetic resonance 
imaging (MRI) of the patient's brain. 
 
1.9 Treatment of Glioma 
The treatment of malignant glioma includes surgery, chemotherapy and 
radiotherapy (Lonardi et al., 2005). Surgical removal remains the mainstay of treatment, 
provided that unacceptable neurologic injury can be avoided, however, the extremely 
infiltrative nature and ill-defined margins of gliomas makes complete surgical removal 
impossible (Lonardi et al., 2005). Depending on the site of the lesion and the condition 
of the patient, surgery can include gross total excision of the tumour using image 
guidance or may be restricted to biopsy (Wheeler et al., 2008). Maximal resection is 
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performed whenever possible in patients with both low-grade and malignant gliomas as 
it has proven to increase the 1-year survival rate by 76.5% when compared to lesser 
extent of resection (Orringer et al., 2012).  
 
Technical advances in neuro-imaging like MRI, MR spectroscopy and surgical 
technology like image guided surgery, intra operative ultrasound and, CT have 
improved and maximized tumour resection, while decreased procedure - related 
morbidity (Dhermain, 2014). A study from the Eastern Co-operative Oncology and 
Radiation Therapy Group (USA) showed a positive correlation between survival and 
extent of resection (Kuhnt et al., 2011). 
 
1.9.1 Radiotherapy 
Radiation therapy is one of the most important treatments for glioma, and 
although it rarely cures glioma, it increases the median survival time of patients when 
compared to supportive care alone. Standardised radiation treatment of glioma involves 
irradiating with 60 gray units (GY), delivered in 30 fractions of 2GY, with conventional 
external beam radiotherapy followed by surgery (Ricard et al., 2013). This dose is too 
low to sterilize the tumour and prevent it’s reoccurrence, but high radiation doses using 
standard fractionation can pose a greater risk of radiation injury to normal brain without 
any survival benefits (Frappaz et al., 1999).  
 
Radio-immunotherapy is a beneficial treatment technique as it aims at 
selectively destroying tumour cells by using radio-labelled monoclonal antibodies 
which target specific antigens expressed only by tumour cells while sparing normal 
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tissues (Westphal et al., 2013). Three step avidin-biotin has been targeted to the 
90
Y-
biotin to the tumour in glioma patients with encouraging results (Paganelli et al., 2001). 
 
1.9.2 Chemotherapy & Alkylating Agents 
Several randomized clinical trials have assessed the role of chemotherapy in the 
improvement of survival for glioma patients (Lonardi et al., 2005), with various 
chemotherapeutic agents having been administered before (neo-adjuvant), 
concomitantly, or post radiotherapy (Ohka et al., 2011). The two major classes of 
chemotherapeutic drugs that are being used currently in the treatment of gliomas include 
the alkylating agents and alkylating-like agents. 
 
Alkylating agents were the first compounds identified to treat cancer (Espinosa 
et al., 2003). These compounds react directly with electron rich atoms in biological 
molecules to form covalent bonds. The chemotherapeutic and cytotoxic effects are 
directly related to the alkylation of DNA (Middleton & Margison, 2003). Nitrosourea 
alkylating agents are commonly used in the treatment of gliomas as they are highly lipid 
soluble and readily cross the blood brain barrier (Zhelev et al., 2008). The main 
nitrosureas employed in glioma treatment are nimustine, carmustine and lomustine 
(Weller et al., 2013). 
 
1.9.2.1 Temozolomide 
Temozolomide (TMZ) (trade name: Temadol in Europe, Temador in the USA) 
is an orally administrated, non-classical alkylating agent derived from dacarbazine and 
was first synthesised in 1984 (O’Reilley et al., 1993; Friedberg, 2001). It is an 
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interesting drug in part because its development was based on chemosensitivity assays 
using a wide variety of cultures of brain-tumour cells (Bower et al., 1997). Surprisingly, 
the other common chemotherapy agents used for brain cancer were developed, not on 
their effect in the laboratory on cultured brain tumour cells, but on cell cultures from 
other types of cancer (Prasad et al., 1980). It is recommended for the treatment of 
patients with malignant gliomas showing recurrence or progression after standard 
therapy (Walker et al., 2011). TMZ shows excellent penetration of the blood brain 
barrier due to its small size and lipophilic properties, with studies showing the CNS 
concentration of the drug to be 30-40% of its plasma concentration (Agarwala, 2000). 
Typically, it is administered orally, once a day for 5 days in a 28-day cycle, has high 
bioavailability and once it crosses the blood-brain barrier it is spontaneously hydrolysed 
to its active form (Wick et al., 2009). TMZ toxicity results from induction of the DNA 
adduct O6-methylguanine (O6M-G) which activates the mismatch repair (MMR) 
system, causing double strand breaks in the DNA, cell cycle arrest in G2/M phase, and 
ultimately apoptosis (Roos et al., 2007; Caporali et al., 2004; Hickman & Samson, 
1999). 
 
The most influential randomized study on TMZ, undertaken by the National 
Cancer Institute of Canada, led to the establishment of concurrent temozolomide and 
radiation therapy for glioma (Hegi et al., 2005). It reported that the two-year survival 
rate of patients increased from 10.4% with radiation alone, to 26.5% with the 
concomitant therapy, establishing TMZ as the current standard treatment for anaplastic 
astrocytomas. TMZ is also being tested in combination with a spectrum of other drugs 
extensively in low-grade gliomas (Dinca et al., 2007).  
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O6-alkylguanine-DNA alkyltransferase (AGT), the MMR pathway and Poly 
(ADP-ribose) polymerase (PARP) are the three different mechanisms of resistance to 
TMZ. With AGT, the alkyl group is removed from the O6 position of guanine bases 
which in turn reverses the cytotoxic lesion of TMZ (Tisdale, 1987). Guanine alkylation 
by TMZ can be counteracted by MGMT (O6-methylguanine DNA methyltransferase). 
Thus, tumour sensitivity to O6-alkylating agents inversely correlates with MGMT 
expression/activity levels, and as MGMT expression is controlled by hypermethylation 
of the promoter gene in tumour tissue, methylation can be used to predict sensitivity to 
TMZ (Hegi et al., 2005; Reifenberger et al., 2012; Bady et al., 2012; Qian et al., 1997). 
During DNA replication O6-MG mispairs with thymine, a pairing recognised by the 
MMR system which removes the thymine leading to repeated insertion of O6-MG and 
ultimately production of DNA strand breaks, p53 activation and apoptosis induction 
(Tentori et al., 2013). However, mutations in one or more protein complexes result in 
MMR pathway deficiency, meaning that cells can tolerate the methylation and cytotoxic 
effects of TMZ. This leads to the unrepaired O6-MG adducts produced by the TMZ 
causing DNA replication to pass the O6-MG adducts without apoptosis (Wedge et al., 
1996). In addition to generating O6-MG, TMZ also methylates DNA resulting in 
adducts that are excised by N-methylpurine DNA glycosylase, producing apruinic 
endonuclease target sites, resulting in gaps that are repaired by the base excision repair 
system (Tentori et al., 2013). PARP-1 is involved in both strand break detection and 
repair processes and in patients treated with TMZ, can be upregulated, leading to 
resistance to treatment effects. 
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1.9.2.2 Cisplatin 
Cis-diamminedichloroplatinum (CDDP) or cisplatin is a platinum containing 
chemotherapeutic drug that despite lacking an alkyl group in its structure is considered 
to be an alkylating-like agent due to its mechanism of action. Currently it is one of the 
most potent drugs used in the treatment of testicular, ovarian, head and neck tumours 
(Janjetovic et al., 2011) and is also used in the treatment of paediatric brain tumours 
(Singh et al., 2010). It is used in both adjuvant and neo-adjuvant treatment of glioma 
(Seifart et al., 2005; Diaz et al., 2005), as a monotherapy or in combination with other 
chemotherapeutic agents to treat recurrent glioblastoma and low grade glioma, and in 
combination with radiotherapy has proven to be effective (Agholme et al., 2012).  
 
The main mechanism of cisplatin antitumor activity is via dative covalent 
interaction with purine bases in the DNA following aquation of the one of the chloride 
ions in cisplatin. The formation of DNA-protein and DNA-DNA crosslinks block the 
proliferation of the tumour cell causing a transient cell cycle arrest at S-phase leading to 
a final G2/M phase arrest, ultimately leading to apoptosis (Janjetovic et al., 2011). 
Cisplatin has other mechanisms of toxicity, including changing cellular transport 
mechanisms, damaging mitochondria, and activation of the p53 and MAPK pathways. 
Several genes activated by p53 are associated with cell cycle arrest, DNA repair, 
apoptosis (CDK inhibitor p21
Waf1/Cip1
), growth arrest and pro-apoptosis (bax). When 
DNA damage goes beyond a critical threshold, and overwhelms the repair mechanisms, 
apoptosis is induced (Wu et al., 2000; Siddik 2003; Hershberger et al., 2002). 
 
As with other chemotherapeutic drugs, several different mechanisms of 
resistance to cisplatin have been described, typically with multiple forms being found at 
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a same tumour site. The mechanisms include a reduction in the intracellular 
accumulation of cisplatin which is generally caused by an inhibition of the drug’s 
uptake due to reduced expression of the high affinity copper transporter (Chen and Kuo, 
2013), an increase in cellular efflux by MRP2, a member of the subfamily C of the 
human ABC (ATP-binding cassette) superfamily (Borst et al., 2000; Leslie et al., 2005), 
or both (Kelland, 2000; Yoshida et al., 1994). Resistance also occurs through 
inactivation by thiol-containing molecules such as glutathione (GSH) and 
metallothionein that increase in concentration when cisplatin is active in the chloride 
deficient cytoplasm, changes that appear to be mediated by the upregulation of the 
transcription factor c-jun (Pan et al., 2002). Similarly to TMZ, the nucleotide excision 
repair (NER) pathway becomes upregulated following treatment, resulting in an 
increase in DNA damage repair following formation of DNA adducts (Galluzzi et al., 
2012). Finally, high expression of HER-2/neu and PI3-K/Akt pathways can lead to 
resistance. HER-2/neu is a proto-oncogene which encodes a receptor tyrosine kinase 
(p185) homologous to the epidermal growth factor receptor (EGFR) that on activation 
sends a downstream signal, which activates the PI3-K/Akt pathway. Akt subsequently 
promotes the phosphorylation of Mdm2 and its translocation to the nucleus where it 
downregulates p53, leading to drug resistance (Oren et al., 2002; Hung and Lau, 1999; 
Siddik, 2003). Along with side effects like ototoxicity, nephrotoxicity and neurotoxicity 
(Hartmann & Lipp, 2003), these factors can limit both the dose and use of cisplatin. 
 
1.10 Non-steroidal Anti-inflammatory Drugs 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a drug class that can have 
anti-pyretic, analgesic and anti-inflammatory effects depending on their dosage (Ligett 
et al., 2014). The class contains a variety of drugs like salicylates, propionic acid 
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derivatives and acetic acid derivatives (Hwang et al., 2004). They mainly function via 
inhibition of cyclooxegenase-1 and 2 (COX-1 and 2) enzymes, which in turn reduces 
the synthesis of pro-inflammatory prostaglandins and thromboxanes. The NSAIDs, 
aspirin, ibuprofen, and naproxen, are all widely used and available over the counter in 
most countries (Lichtenberger et al., 1995). 
 
1.10.1  Aspirin 
Acetylsalicylic acid (Fig 1.1), also known as aspirin, is one of the most widely 
used medicines in the world (Zhang et al., 2014). It was formulated as a stable 
compound by mixing acetic and salicyclic acids in 1897 by Felix Hoffman, in a lab 
owned by Friedrich Bayer (Hafizullah & Hafiz, 2013), and by 1899, had become 
Bayer’s best-selling drug worldwide (Budge et al., 2014). In the same year it was 
registered under the name ‘Aspirin’ and by 1904 it was available in the tablet form, 
achieving widespread global use for the treatment of several conditions such as fever, 
pain, and rheumatic inflammation (Vane & Botting, 2003).  
 
However, despite its extensive use, the mechanism of its action wasn’t well 
understood until in 1971, when John Vane published his results in the journal Nature, 
explaining that the mechanism of action involved the inhibition of prostaglandin 
production, a discovery that led to him being awarded the Nobel Prize for his work on 
prostaglandins in 1982 (Oates, 1982). 
 
Aspirin, an acetyl derivative of salicyclic acid synthesized via esterification of 
salicylic acid, is a white, crystalline substance with a very weak acidic nature and 
boiling point of 140
o
C and melting point of 136
o
C (Kim et al., 1984; Wheatley, 1964). 
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Figure 1.1: Chemical structure of aspirin 
Obtained from: 
http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=56141  
 
In addition to irreversibly inhibiting the COX-1 and COX-2 enzymes (Pascale et 
al., 2012), aspirin has also been shown to uncouple oxidative phosphorylation in 
mitochondria, act as a proton transporter, and modulate the NF-κB signalling pathway 
(Somasundaram et al., 2000; Shi et al., 1999; Stark et al., 2001). In addition, a study on 
the proliferation of coronary artery endothelial cells demonstrated that aspirin inhibits 
proliferation by upregulating p53, leading to cell cycle arrest (Ranganathan et al., 2003). 
 
1.10.2  Aspirin and Cancer 
The first evidence which supported the therapeutic use of aspirin in the 
treatment of cancer was reported by Kune and colleagues in 1988, who demonstrated a 
decreased risk of developing colorectal cancer (CRC) with the use of aspirin (Kune et 
al., 1988). The trial involved over 700 patients with CRC and a similar number of 
controls and found a reduction of 40% in the risk of developing CRC amongst 
participants who were administered aspirin on a regular basis. Following this seminal 
publication, several studies have proved the importance of aspirin in the prevention of 
cancer (Rosenberg et al., 1991; Muscat et al., 1994; Smalley et al., 1999), and meta-
analysis of several trials examining the effects of aspirin on cardiovascular system have 
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also concluded that regular use of aspirin reduced the risk of cancer development (Chan 
et al., 2011; Lee et al., 2005).  
 
Each meta-analysis has revealed different positive effects of aspirin use in the 
treatment and prevention of CRC. Two large randomized trials involving more than 
7000 participants, the British Doctors Aspirin Trial and UK-TIA Aspirin Trial, where 
the long term effects of aspirin was studied, concluded that use of as much as 300 mg of 
aspirin daily for a term of five years was effective in reducing the risk of CRC 
(Flossman et al., 2007). Meta-analysis of four randomized trials involving more than 
14,000 participants that had the primary aim of determining the efficacy of aspirin in the 
prevention of cardiovascular disease revealed that daily aspirin use reduced the twenty 
year CRC mortality by 34% (Chan et al., 2011). Additionally, the study showed that the 
risk of developing advanced adenomas was reduced by 28%. However, it was 
concluded that further investigation regarding the daily dose of aspirin required to 
reduce cancer risk, and to determine its underlying mechanism, was required. 
 
Aspirin has also been suggested to have a protective role in several other 
cancers besides CRC (Spector et al., 2005; Baron, 2004; Jacobs et al., 2007). One large 
study that involved the meta-analysis of fifty one different trials involving more than 
77,000 patients revealed that aspirin reduced the risk of cancer following only three 
years of use, and the risk of cancer related death following five years of use (Rothwell 
et al., 2012). Importantly, the results showed that the effect was independent of sex, age 
or smoking status. The study also suggested that a low dose of aspirin (75-300mg) 
reduced the overall risk of cancer by 25% within a period of 3 years, and the rate 
dropped even further to 37% after 5 years of regular consumption. However, an 
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increased risk of major bleeding was observed, although this risk disappeared following 
3 years of use. 
 
1.10.3  Aspirin and Metastasis 
As well as reducing overall cancer incidence and related deaths, recent studies 
have established a protective effect of aspirin in relation to metastases, demonstrating 
benefits not just linked to primary tumour development (Algra & Rothwell, 2012; 
Rothwell et al., 2012). Meta-analysis of five separate trials examining the use of aspirin 
either by itself or combination with other NSAIDs, but where aspirin was the most 
commonly used drug, reported that regular use of aspirin reduced the risk of cancers 
with distant metastasis by 31% (Algra & Rothwell, 2012). Another pooled study which 
involved five randomized trials with more than 17,000 patients demonstrated a 36% 
reduced risk of death by distant metastases (Rothwell et al., 2012). It also showed that 
the reduction in risk of death by metastasis involving adenocarcinoma was 46%. 
 
 
1.10.4  Aspirin and Glioma 
While there is insufficient clinical data to currently support the use of aspirin in 
the treatment or prevention of brain tumours, several in-vitro studies on human 
glioblastoma cell lines and rat glioma cell lines have reported a cytotoxic effect of 
aspirin (Hwang et al., 2004; Kim et al., 2009a). A study combining an in vitro rat 
glioma cell line and in vivo rat models concluded that, in rat cell lines, aspirin 
administered at a dosage recommended for treatment of rheumatoid arthritis, inhibited 
the growth of the cells (Aas et al., 1995). In vivo, inoculated tumours showed reduced 
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growth following aspirin treatment, but other NSAIDS such as indomethacin and 
piroxicam didn’t show similar effects, leading to the conclusion that the anti-
proliferative effect was not due to the inhibition of prostaglandin production.  
Interestingly though, Hwang and colleagues demonstrated that both aspirin and 
indomethacin inhibited the synthesis of prostaglandin E2 in the C6 rat glioma cell line, 
that low dose aspirin was as effective as high dose, and suggested a link between 
prostaglandin production and cancer prevention (Hwang et al., 2004). More recently, an 
in-vitro study using the A172 human glioblastoma cell line demonstrated that aspirin 
induced apoptosis via the down regulation of IL-6 dependent Stat3 signalling (Kim et 
al., 2009). Given some of the conflicting reports in the literature, and the current lack of 
clinical data, further research is required to determine the effects of aspirin in human 
glioma patients and the therapeutic pathway/s involved. 
 
1.11 Aspirin Analogues 
In addition to its therapeutic effects, aspirin produces side-effects, especially at 
higher doses. These include increased risk of bleeding, and both gastrointestinal and 
renal disturbances, resulting in a drive to develop novel derivatives (analogues) of 
aspirin and other NSAIDs which retain the potent antineoplastic effects with reduced 
adverse effects (Deb et al., 2011; Hursthouse et al., 2010). Subsequently, several 
promising analogues have been developed and tested on human cancer cell lines (Deb et 
al., 2011; Basudhar et al., 2013). One such analogue, IPA/NO, which is a nitric oxide 
(NO) releasing aspirin-derivative, was shown to reduce cell viability of the non-small 
cell lung carcinoma A549 cell line with an IC50 of 90 M, a concentration at which 
aspirin had no effect on viability (Basudhar et al., 2013). Another novel aspirin 
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analogue, 4-hydroxy benzoate zinc (4HBZ) reduced cell viability of primary chronic 
lymphatic leukemia cells with an IC50 of 330M, significantly higher than that of 
aspirin on the same cell line (Pepper et al., 2011).  
 
Deb and colleagues investigated the efficacy of several novel aspirin analogues 
in vitro using the SW480 colorectal cell line (Deb et al., 2011). In comparison to a 20% 
reduction in cell viability by aspirin at a concentration of 0.5mM, one analogue, PN517 
(Fig 1.2) reduced cell viability by 65% at the same concentration (Deb et al., 2011). The 
efficacy of PN517 in viability assays was similar to that of irinotecan, a standard 
chemotherapeutic drug used in the treatment of CRC. They demonstrated that treatment 
with PN517 for forty eight hours induced apoptosis at a rate significantly greater than 
non-treated controls. 
 
The preparation of PN517 involves modifying bis(2-carboxyphenyl) succinate 
(PN508), which is effectively a double aspirin molecule, meaning that PN517 resembles 
two aspirin molecules bound together by a double carbon bond (Fig 1.2). It is suggested 
that this double carbon bond provides the molecule with rigidity when compared to 
PN508 (Deb et al., 2011). 
 
 
Figure 1.2: Chemical structure of PN517 
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1.12 Combination Therapies 
Glioblastoma multiforme is highly resistant to the current treatment regimens, 
which is evident from its poor prognosis. This resistance is, to a large extent, due to the 
high invasiveness and proliferation rate of GBM, and as a result current treatment 
strategies are mainly palliative (Torres et al. ,2011). As has been described, diminishing 
responses to standard therapeutic drugs like temozolomide and cisplatin over the course 
of a chemotherapy can result from tumours acquiring defence mechanisms by 
overexpressing drug efflux pumps, increasing drug metabolism, enhancing self-
repairing ability or expressing mutations at drug targets (Gottesman, 2002).  To reduce 
drug resistance, combination chemotherapy has long been accepted in cancer treatment 
(Hu et al., 2010).  
 
It has been suggested that applying multiple drugs with different molecular 
targets at doses reduced in comparison to monotherapies, can raise the genetic barriers 
that need to be overcome for glioblastoma mutations, thereby delaying its adaptation 
process. Conversely, it has been reported that multiple drugs targeting the same cellular 
pathways can function synergistically for higher efficacy and target-selectivity (Lehàr et 
al., 2010). 
 
Several studies and clinical trials have used drug combinations in treatment of 
glioblastoma with varying results (Kondo et al., 1995; VanderSpek et al., 2008; 
Mishima et al., 2000; Baumann et al., 2004; Friday & Adjei, 2008). Temozolomide has 
shown moderate therapeutic effect on its own, however, when combined with 
radiotherapy or other anticancer drugs, it has displayed increased efficacy (Zhu et al., 
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2014). Combining aspirin with a highly resistance-forming drug like cisplatin could 
help improve the cytotoxicity of the chemotherapeutic drug by altering the cellular 
response (Cheng et al., 2014). Aspirin can also be beneficial in reducing the extent of 
cisplatin-induced side effects, mainly related to hearing and balance (Pathak et al., 
2014). 
 
1.13 Apoptosis 
Apoptosis was first described in 1972 (Kerr et al., 1972) with the term 
originating from the Greek meaning falling (ptosis) off (apo). It is an active form of cell 
death whose control and mediation is cell-specific and contextual, is highly conserved 
throughout evolution, and is important during development and homeostasis in the adult 
(Bai et al., 1999; Hetts, 1998).  The process allows for the removal of damaged, injured, 
infected and incompetent cells from the body both quickly and efficiently. Apoptosis is 
different from necrosis, an uncontrolled form of cell death characterized by cell 
swelling and mitochondrial damage leading to rapid depletion of energy levels; a 
breakdown of homeostatic control; cell membrane lysis and release of the intracellular 
contents. This leads to an inflammatory response, with oedema and damage to the 
surrounding cells (Yeh, 1997).  
 
The course of apoptosis is in stark contrast to that of necrosis. It is a controlled 
and contained process, activated by either external or internal stimuli (Kuan & Passaro, 
1998).  Initially, the cell shrinks, loosing contact with surrounding cells, and starts to 
display intracellular proteins on the cell surface. Chromatin condensation and DNA 
cleavage occurs which can be observed as DNA laddering during gel electrophoresis 
(Steller, 1995; Yeh, 1997). With the cell membrane still intact, blebbing occurs 
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releasing fragments of the cell known as apoptotic bodies (Hetts, 1998). Unlike 
necrosis, this process is relatively rapid, reaching completion in approximately two 
hours (Kuan and Passaro, 1998). 
 
Triggers of apoptosis can be either extrinsic or intrinsic (Fig 1.3), activating 
separate pathways initially which ultimately converge on the caspase system of 
enzymes to execute their function. Extrinsic triggers include activation of death 
receptors, such as Tumour Necrosis Factor receptors, or removal of survival promoting 
signals such as the growth factor PDGF (Rich et al., 2000; Best et al., 1999).  Intrinsic 
activators of apoptosis include increased oxidative stress (Desagher & Martinou, 2000). 
 
Both extrinsic and intrinsic pathways converge on caspase enzymes, an 
evolutionary conserved family of cysteine proteases, the “central executioners” in 
apoptotic cell death.  Caspases are synthesized as enzymatically inert zymogens, 
requiring proteolytic cleavage to induce their activation (Gibbons & Pollman, 2000; 
Hengartner, 2000), generally resulting in a serial sequence of caspase activation known 
as the caspase cascade.  Activation of caspase 8 and caspase 9, known as initiator 
caspases, results in subsequent cleavage and activation of downstream effector caspases 
such as caspase 3, caspase 6 and caspase 7.  The effector caspases are responsible for 
the induction of the biochemical and morphological changes associated with apoptosis, 
and are usually more abundant and active than the initiator caspases (Gibbons and 
Pollman, 2000; Hengartner, 2000).   
 
Caspase 9 is activated as part of the intrinsic pathway through association with 
the apoptosome which consists of cytochrome c, an adapter molecule Apaf-1 (apoptosis 
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protease-activating factor), and pro-caspase 9 (Hengartner, 2000; Gupta, 2001). 
Activation of death receptors leads to the formation of the Death Inducing Signalling 
Complex (DISC), the formation of which leads to the cleavage and activation of pro-
caspase 8. Ultimately, caspase 8 and 9 cleave and activate caspase 3, caspase 6 and a 
number of other substrates resulting in the biochemical and morphological 
characteristics of an apoptotic cell.  
 
 
Figure 1.3: Schematic representation of the intrinsic and extrinsic apoptosis 
pathways 
(Zacks et al., 2004). 
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1.14 Autophagy 
As with apoptosis, autophagy is an evolutionary conserved process where 
double-membrane vesicles form containing sections of the cytosol and intracellular 
organelles, preparing them  for lysosomal degradation (Yang & Klionsky, 2010; Sui et 
al., 2011). This process can eliminate damaged organelles and macromolecules, 
providing protection against carcinogenesis, but can also lead to tumour cell survival in 
response to stressors such as hypoxia or chemotherapeutic damage (Kondo et al., 2005; 
Maycotte & Thorburn, 2011; Janku et al., 2011). Conversely, persistent autophagy can 
stimulate cell death following chemotherapy by inducing apoptosis. Intracellular 
signalling pathways involved in autophagy are still being characterised, but 
phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) and AMP-
activated protein kinase (AMPK) are critical regulators (Glick et al., 2010) (Fig 1.4).  
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Figure 1.4: Schematic representation of the PI3K/mTOR signalling pathways in 
autophagy 
(Fleming et al., 2011)  
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In GBM, autophagy is enhanced in response to hypoxia promoting tumour cell 
survival (Hu et al., 2012). In response to this, a recent clinical trial was launched to 
examine the effect of combining an autophagy inhibitor with temozolomide and 
radiation for the treatment of GBM. The results from the trial suggested a mechanistic 
interaction between temozolomide and the inhibitor (Rosenfeld et al., 2010). The theory 
is that autophagy inhibitors such as chloroquine will result in the accumulation of 
autophagic vacuoles, resulting in the induction of cell death in an non-apoptotic manner 
(Geng et al., 2010). 
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1.15 Hypothesis and Aims 
Working Hypothesis: Can combined treatment of aspirin or aspirin analogues 
with other chemotherapeutics lead to enhanced efficacy in in vitro models of glioma? 
 
Main Aim: The main aim of the study is to investigate the effect of the 
chemotherapeutics temozolomide and cisplatin and aspirin and aspirin analogues alone 
or in combination on glioma cell death and to determine the mechanism of action of 
these drugs in combination. 
 
Specific Aims: 
1. To determine both time course and dose dependent effects for 
chemotherapeutics and an aspirin-like drug by themselves or in combination, on 
glioma cell lines. 
2. To determine the effects of drug treatment on cell proliferation 
3. To investigate the mechanism of action of cell death for the combined treatments 
by examining apoptotic markers and pathways such as caspase-8 and 9 or the 
possible involvement of autophagy. 
4. To confirm the cytotoxic effects of the drug treatment via confocal microscopy. 
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2 Materials and Methods 
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2.1 Materials 
All reagents used were of the highest grade commercially available and, with the 
exception of PN517 which was supplied by Dr Iain Nicholl (Wolverhampton 
University, UK), obtained from the following suppliers: 
 
Fisher Scientific (Loughborough, UK) 
Ethanol, 25 & 75 cm
2
 filter cap, angled neck tissue culture flasks, serological pipettes, 
50 & 15 ml centrifuge tubes, multi well dishes, PBS tablets, Foetal Bovine Serum, 8-
well LabTek Chamber slides 
 
Sigma-Aldrich (Poole, UK) 
Trypan blue, 3-methylanadine, temozolomide, cisplatin, aspirin, bovine serum albumin, 
DMSO 
 
Life Technologies (Paisley, UK) 
PrestoBlue™ Cell Viability Reagent, Alexa Fluor® 488 annexin V/Dead Cell Apoptosis 
Kit for Flow Cytometry, CFDA-SE 
 
Lonza (Slough, UK) 
MEM Eagle with EBSS w/o L-Glut, MEM Eagle NEAA (100x), L-Glutamine 200 mM, 
Trypsin/EDTA 10x, Sodium Pyruvate Solution 100 mM 
 
BD Biosciences (Plymouth, UK) 
FACS Tubes, BD FACSTM Shutdown Solution, BD FACSTM Clean Solution, BD 
FACSFlowTM Sheath Fluid, BD FACSRinse Solution 
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Promega (Southampton, UK) 
Caspase-Glo(R) 8 Assay, Caspase-Glo(R) 9 Assay 
 
ECACC (Porton Down, UK) 
U-87 MG Grade IV Human Glioblastoma Cell Line 
 
ATCC (Manassas, VA, USA) 
SVG-P12 human foetal astroglial cell line 
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2.2 Cell Culture Methods 
2.2.1 Cell Maintenance 
U-87 MG and SVG-p12 cells were maintained in Eagles Minimum Essential 
Media (EMEM), supplemented with 10 % Foetal Bovine Serum (FBS), L-glutamine (2 
mM), 1 % Non-Essential Amino Acids (NEAA), sodium pyruvate (1 mM) in a 37
o
C 
humidified atmosphere containing 5% CO2. When a maximum confluence of 80% was 
reached, cell monolayers were washed with phosphate buffered saline (PBS) solution, 2 
ml of 1 x trypsin-EDTA was added, the flasks returned to the incubator to allow cells to 
detach, and 8 ml of media was added and the cells pipetted gently to ensure a single cell 
suspension. Cells were either passaged 1:4 into flasks to maintain the cell line or seeded 
into dishes for experimental analysis. 
 
2.2.2 Growth Curve 
To determine the growth rate of the cell lines, growth curve analysis was 
performed over a period of nine days. Cells were seeded in 6 well plates at a density of 
20,000 cells per well, and each day 3 wells were trypsinised and the cell number 
determined by counting using a haemocytometer.  
 
2.2.3 PrestoBlue® Cell Viability Assay 
PrestoBlue
®
 is a resazurin-based cell permeable viability indicator that is 
reduced in living cells, changing in colour from blue to red (absorbance 570 nm), and 
becoming highly fluorescent (excitation 535 nm/emission 612 nm), with it being 
possible to quantitatively measure both changes.  
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As the greatest variable in viability assays is cell number, linearity of 
fluorescence versus cell number was determined. Cells were seeded at 0, 50, 100, 250, 
500, 1000, 5000 and 10,000 cells/well in a 100 l volume of media(EMEM) and 
cultured for 24 or 48 hours before incubating with PrestoBlue
®
 (10 l/well) for 1 hour 
and measuring fluorescence. 
 
Concentration response assays were performed to determine the IC50 values for 
aspirin, cisplatin, temozolomide and PN517 in both U-87 MG and SVP-p12 cell lines. 
Briefly, cells were seeded at 1000 cells per well in 90 l of media, cultured for 24 hours 
before drug treatment with a range of drug concentrations(10M – 10mM) of volume 
10 l each, and viability determined by PrestoBlue® assay following either 24 or 48 
hours of treatment. Appropriate media and vehicle controls were also added in a 10 l 
volume.  
 
Drug combination assays were performed by seeding both U-87 MG and SVP-
p12 cell lines at 1000 cells per well in 90 l of media and culturing for 24 hours before 
drug treatment (10 l) with the IC50 value for each drug as determined by the 
concentration response assays. With cisplatin, two different concentrations were used: 
Cisplatin high – concentration corresponding to the IC50 at 24 hoursin the U87-MG 
cells; Cisplatin low – concentration corresponding to the IC50 at 24 hours in the SVG-
P12 cells. 
 Three different combination protocols were performed. The first simply combined drug 
treatments and determined cell viability by PrestoBlue
®
 assay following 2, 4, 8, 12, 24 
and 48 hours of treatment. The second protocol staggered drug additions, treating cells 
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with aspirin or PN517 for 24 hours before adding cisplatin for a further 24 hours and 
determining cell viability by PrestoBlue
®
 assay. The third protocol involved multiple 
treatments with aspirin or PN517, with fresh drugs being added at 12, 24 and 36 hours 
and the old media being removed. At the 36 hour time point, cisplatin was added in 
combination and cell viability subsequently determined at 48 and 72 hours by 
PrestoBlue
®
 assay. 
 
The contribution of autophagy to changes in cell viability was determined 
using the selective autophagy inhibitor, 3-methyladenine (3-MA) (Heckmann et al., 
2013). Cells were treated with 3-MA (0.5mM) for 1 hour prior to the addition of either 
cisplatin or PN517 and incubation for 24 hours, before determination of cell viability by 
PrestoBlue
®
 assay. 
 
2.2.4 CFDA-SE Cell Proliferation Assay 
In order to examine cell proliferation, both the U-87 MG and SVG-p12 cell 
lines were seeded at a density of 150,000 cells per well in 6 well plates. Cells were 
treated with the proliferation marker CFDA-SE (0.5 M) in PBS for 30 minutes, 22 
hours after seeding (Shedlock et al., 2010). The PBS-CFDA-SE solution was discarded 
and 3 ml of fresh media added to each well. 24 hours after seeding, non-CFDA-SE 
treated cells and non-drug treated control CFDA-SE treated cells were harvested for 
flow cytometric analysis. The drug treatments (0.1 mM) were added, and the plates 
incubated for a further 24, 48 and 72 hours prior to harvesting for flow cytometric 
analysis. Cells were harvested by trypsinisation and centrifugation, washed with PBS 
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before suspension in 100l of PBS-0.1% BSA in FACS tubes, and maintained on ice 
prior to analysis. 
 
2.2.5 Apoptosis Assay, Annexin-V/Propidium Iodide 
Induction of apoptosis was examined in both the U-87 MG and SVG-p12 cell 
lines following drug treatment for 24 and 48 hours. Briefly, cells were seeded at a 
density of 150,000 cells per well in 6 well plates, incubated for 24 hours prior to drug 
treatment prior to harvesting by trypsinisation and centrifugation following a further 24 
and 48 hours of incubation. As per the manufacturers protocol, cell pellets were 
resuspended in 1 x binding buffer containing propidium iodide (1:200 dilution of stock) 
and annexin-V (1:40 dilution of stock) and incubated at room temperature for 15 
minutes prior to analysis. Unless otherwise stated, at all stages following harvesting, 
cells were maintained at 4
o
C. 
 
2.2.6 Flow Cytometry 
All cells were analysed using a FACSAria (BD Bioscience, Franklin Lakes, 
New Jersey, USA) equipped with an air-cooled 15 mW argon laser emitting at a fixed 
wavelength of 488 nm. The fluorescence filters and detectors used were all standard 
with green fluorescence collected in the FL1 channel (530 ± 30 nm) and red in the FL2 
channel (615 ± 25 nm) . Samples were gated on forward scatter (FS) versus side scatter 
(SS) to exclude debris and clumps. The cells were analysed using algorithmic amplifier 
to determine the percentage of stained cells and their mean fluorescence intensity. 
During data acquisition, a “live gate” was set on the appropriately stained cell 
population and a total of 10,000 gated events were acquired for each treatment.  
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2.2.7 Assay of Caspase 8 & 9 Activity 
The Caspase-Glo
®
 assays are luminescent assays that determined caspase 
activity based on the production of a luminogenic substrate following cell lysis (Fig 
2.1). As per manufacturer’s instructions, cells were seeded at a density of 10,000 cells 
per well in white walled opaque clear bottomed 96 well plates and incubated overnight. 
Cells were drug treated for 12, 24 and 48 hours prior to a one step lysis and detection 
protocol with either the caspase 8 or 9 reagent. Prior to addition of the mixture in a one 
to one ratio with the media under low light conditions, the cells were equilibrated at 
room temperature for 10 minutes. Following addition, the plate was protected from light 
using foil, shaken at 500 rpm for 30 seconds using an orbital shaker, and incubated at 
room temperature for 1 hour. The luciferase based luminescent signal, proportional to 
the amount of caspase activity, was detected using a TECAN plate reader. 
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Figure 2.1: Schematic diagram depicting the Caspase-Glo assay protocol 
(Adapted from www.promega.co.uk)  
 
2.2.8 Confocal Laser Scanning Microscopy 
The U-87 MG and SVG-p12 cell lines were seeded on 8 well chamber slides at 
a density of 5000 cells per well and cultured overnight prior to drug treatment as per the 
cell viability drug combination assay (Section 2.2.3). After 24 hours incubation, the 
media was removed and the cells washed twice with PBS at 37
o
C, before being stained 
with annexin-V and propidium iodide as per the flow cytometry apoptosis protocol 
(Section 2.2.5). Following staining, the cells were washed with PBS before a final 100 
l of PBS was added prior to confocal analysis. 
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Cells were observed using a Zeiss LSM 510 laser scanning confocal 
microscope (Zeiss, Oberkochen, Germany) using a Zeiss Plan-Neofluar 40 x 1.3 oil 
immersion objective and pinhole of 100 m. Annexin-V and propidium iodide were 
excited using a 488 nm argon / krypton laser, with annexin-V being detected with a 
505-530 nm band pass filter and propidium iodide with a 560 nm long pass filter. The 
images were processed with Zeiss LSM Image Browser. 
 
2.2.9 Statistical Analysis 
Unless otherwise indicated, results of each assay were normalised and 
expressed as a percentage of untreated control cell populations. Data were expressed as 
mean ± SEM of at least three independent experiments with different cell passages. 
Comparison between experimental groups was performed using either two-way or one-
way ANOVA with Bonferroni’s Post-Hoc test. p - values ≤ 0.05 were considered as 
statistically significant. 
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3 Results 
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3.1 Growth Curves 
As one factor influencing the results of viability assays is the proliferation of 
cells, growth curves were performed with both the U-87 MG and SVG-p12 cell lines to 
identify any lag phase in their initial growth period or plateau following prolonged 
incubation (Fig 3.1). The growth rate of both cell lines was approximately linear for the 
first six days of incubation, subsequently approaching a plateau at day eight. The assay 
indicates a doubling time of approximately two days for the U-87 MG cell lines, and 
three days for the SVG-p12 cell line. 
 
3.2 Cell Viability 
3.2.1 Effect of increasing cell number on cell viability 
The relationship between cell number and fluorescence using the PrestoBlue cell 
viability assay was determined by performing an assay using increasing number of cells 
(Fig 3.2). Following 24 hours of culture, a linear relationship between cell number and 
fluorescence is observed for both the U-87 MG (R
2
 = 0.93) and the SVG-p12 cell lines 
(R
2
 = 0.93) across the initial seeding density range of 0 – 10,000 cells per well.  
Following 48 hours of culture, fluorescence was linear up to 2500 cells per well (fit not 
shown), but when all cell densities were included, fluorescence began to saturate above 
that cell number for both cell lines. 
 
3.2.2 Concentration Response Assays 
Initial concentration response assays aimed to establish the IC50 values for 
aspirin, PN517, and the standard chemotherapeutics temozolomide and cisplatin using 
the glioblastoma cell line U-87 MG and the control SVG-p12 cell line (Figs 3.3 & 3.4). 
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Following 24 hours of drug treatment, aspirin reduced the viability of both cell lines, 
with an IC50 value in U-87 MG cells of 3.2 mM and in the SVG-p12 cell line of 3.9 mM 
(Fig 3.3). Following 48 hours of drug treatment, these values were 3.5 mM and 2.7 mM 
respectively. Cisplatin also reduced cell viability in a concentration dependent manner 
following both 24 and 48 hours of incubation, with IC50 values at 24 and 48 hours in the 
U-87 MG cell line of 100 M and 9 M respectively. In the SVG-p12 cell line, 
respective IC50 values of 8 M and 22 M were observed. The aspirin analogue PN517 
also reduced cell viability in a concentration dependent manner in both cell lines. In the 
U-87 MG cell line, following 24 and 48 hours of drug treatment, respective IC50 values 
of 1.4 mM and 1.9 mM were observed (Fig 3.4). In the SVG-p12 cell line, the IC50 
value for PN517 was 1.7 mM following 24 hours of drug treatment, and 1.8 mM 
following 48 hours. The current gold standard chemotherapeutic drug for the treatment 
of glioblastoma, temozolomide, was also tested in both cell lines, but following both 24 
and 48 hours of drug treatment in the two cells lines, the maximum effect of treatment 
resulted in a 33% reduction in viability (Fig 3.4, panel D), meaning that no reliable IC50 
value for temozolomide could be determined. 
 
A Two-Way ANOVA was performed on the combined data from aspirin, 
cisplatin, PN517, and temozolomide treatments, and it was found that the U-87 MG 
data displayed homogeneity of variance (Shapioro-Wilks and Levene’s Test both p < 
0.05). There was a significant main effect for drug (F3,120 = 127.719, p < 0.001), for 
concentration (F7,120 = 164.264, p < 0.001), and also a significant interaction effect 
(F13,120 = 16.709, p < 0.001). Subsequent Post-Hoc analysis, Bonferroni and a One-Way 
ANOVA comparison, was performed to determine where the differences lay. The effect 
of cisplatin was found to be significantly different from aspirin (p < 0.03) and 
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temozolomide (p < 0.001), and importantly, the effect of PN517 was significantly 
different from temozolomide (p < 0.01). 
 
The SVG-p12 data also displayed homogeneity of variance (Shapioro-Wilks and 
Levene’s Test both p < 0.05). There was a significant main effect for drug (F3,120 
=301.538, p < 0.001), for concentration (F7,120 = 166.944, p < 0.001), and also a 
significant interaction effect (F13,120 = 23.782, p < 0.001). Subsequent Post-Hoc 
analysis, Bonferroni and a One-Way ANOVA comparison, was performed to determine 
where the differences lay and found that the effect of cisplatin was significantly 
different from aspirin (p < 0.001), temozolomide (p < 0.001) and PN517 (p < 0.001). 
Again, the effect of PN517 was significantly different from temozolomide (p < 0.001). 
 
3.2.3 Combination Treatment Assays – Simultaneous Drug Addition 
Following the determination of IC50 values from the concentration response 
assays, these values were used for the subsequent combination treatment assays. The 
initial assays simply tested these IC50 concentrations on their own or in combination, 
with treatments being added simultaneously and incubated for 2, 4, 8, 12, 24 and 48 
hours prior to determination of viability using the PrestoBlue
®
 assay. Again, both the U-
87 MG (Fig 3.5) and the SVG-p12 (Fig 3.6) cell lines were tested. 
 
Using the U-87 MG cell line, following 2, 4 or 8 hours of drug treatment, no 
significant change in cell viability was observed (Fig 3.5, panels A - C). However, 
following 12, 24 and 48 hours of treatment, significant changes were observed (Fig 3.5, 
panels D – F). A One-Way ANOVA was performed on the results as the data exhibited 
normality (Shapiro-Wilk’s and Kolmogorov-Smirnov, p > 0.05). Analysis found that 
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there was a significant difference between groups at 12 hours (F9,29 = 25.007, p < 
0.001), 24 hours (F9,29 = 31.951, p < 0.001), and 48 hours (F9,29 = 68.768, p < 0.001), so 
Post-Hoc tests were performed to determine where the differences lay. All treatments at 
12 hours were significantly different from control (p < 0.001) apart from cisplatin (low) 
(p = 0.093). The combination of PN517 with cisplatin (high) was significantly different 
from cisplatin (high) alone (p < 0.005). Additionally, the combination of aspirin with 
cisplatin (high) was significantly different from cisplatin (high) alone (p < 0.05). 
Following 24 hours of drug treatment it was found that all treatments were significantly 
different from control (p<0.05) apart from cisplatin (low) (p = 0.215). The combination 
of PN517 with cisplatin (low) was significantly different from cisplatin (low) alone (p < 
0.05), as was the combination of cisplatin (high) with PN517 when compared to 
cisplatin (high) alone (p < 0.001). Additionally, the combination of aspirin with 
cisplatin (high) was significantly different from cisplatin (high) alone (p < 0.005). 
Lastly, it was found that all groups following 48 hours of drug treatment were 
significantly different from control (p < 0.001) apart from cisplatin (low) (p = 0.083) 
and aspirin in combination with cisplatin (low) (p = 0.112). The combination of PN517 
with cisplatin (high or low) was significantly different from cisplatin (high or low 
respectively) alone (p < 0.001). Additionally, the combination of aspirin with cisplatin 
(high) was significantly different from cisplatin (high) alone (p < 0.005).  
 
A similar pattern was observed using the SVG-p12 cell line (Fig 3.6). No 
significant effect on cell viability was found following 2 or 4 hours of drug treatment 
(Fig 3.6, panels A & B), but again, significant decreases in viability were recorded with 
the longer incubation times (Fig 3.6, panels C - F). A One-Way ANOVA was 
performed on results as the data exhibited normality (Shapiro-Wilk’s and Kolmogorov-
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Smirnovs, p > 0.05), and a significant difference between groups at 8 hours (F9,29 = 
3.444, p = 0.01), 12 hours (F9,29 = 11.353, p = 0.001), 24 hours (F9,29 = 10.033, p = 
0.001), and 48 hours (F9,29 = 14.354, p = 0.001) was observed, so Post-Hoc tests were 
performed to determine where the differences lay. At 8 hours, no individual treatment 
produced a significant effect. All treatments at 12 hours were significantly different 
from control (p < 0.001) apart from aspirin, cisplatin (low) and aspirin-cisplatin (low) (p 
> 0.05). The combination of PN517 with cisplatin (low) was significantly different from 
cisplatin (low) alone (p < 0.05). Following 24 hours of drug treatment, all groups were 
significantly different from control (p < 0.001) apart from aspirin, cisplatin (low and 
high) and aspirin-cisplatin (low) (p > 0.05). The combination of PN517 with cisplatin 
(low) was significantly different from cisplatin (low) alone (p < 0.05). Finally, all 
treatments at 48 hours were significantly different from control (p < 0.001) apart from 
aspirin, cisplatin (low) and aspirin-cisplatin (low) (p > 0.05). The combination of 
PN517 with cisplatin (low) was significantly different from cisplatin (low) alone (p < 
0.005).  
 
3.2.4 Combination Treatment Assays - Staggered  
The next series of experiments investigated the effect of staggering the 
combination treatments, where cells were treated with aspirin or PN517 for 24 hours 
before adding cisplatin for a further 24 hours (Fig 3.7). The combination of PN517 with 
cisplatin reduced U-87 MG cell viability to 25 % (cisplatin low) and 18 % (cisplatin 
high) of control. A One-Way ANOVA was performed on U87-MG results (Fig 3.7, 
panel A) as the data exhibited normality (Shapiro-Wilk’s and Kolmogorov-Smirnov, p 
> 0.05), and a significant difference between the groups was observed (F9,29 = 30.387, p 
< 0.001). Post-Hoc tests were subsequently performed to determine where the 
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differences lay and all treatments were significantly different from control (p < 0.001), 
however, the combination of PN517 with cisplatin (low or high) was not significantly 
different from the respective cisplatin mono-treatment.  
Similar results were observed in the SVG-p12 cell line (Fig 3.7, panel B) with 
the combination of cisplatin (low and high) with PN517 reducing cell viability to 31 % 
and 12 % of control. A One-Way ANOVA was performed on the results as the data 
exhibited normality (Shapiro-Wilk’s and Kolmogorov-Smirnov, p > 0.05) and a 
significant difference between the groups was found (F9,29 = 29.127, p <0.001). Post-
Hoc analysis found that all treatments were significantly different from control (p < 
0.001), but again, the combination of cisplatin (high or low) with PN517 was not 
significantly different from the cisplatin treatment alone. 
 
3.2.5 Combination Treatment Assays - Multiple 
As the major cytochrome P450 enzyme responsible for the metabolism of 
aspirin is expressed in the U-87 MG cell line (data not shown), a third protocol was 
investigated where aspirin or PN517 were added repeatedly at 12, 24 and 36 hours 
before subsequent treatment with cisplatin and determination of viability at 48 and 72 
hours (Fig 3.8). It was assumed that repeated drug treatment might help in maintaining 
the drug concentration following it’s metabolism via cytochrome P450 enzyme, thereby 
enhancing its cytotoxic effect. 
 
In the U-87 MG cell line, PN517 or cisplatin alone reduced cell viability to 80% 
and 35% of control respectively after 48 hours of drug treatment (Fig 3.8, panel A). The 
combination of PN517 with cisplatin reduced viability to 34% of control at 48 hours. 
Following 72 hours of drug treatment (Fig 3.8, panel C), cisplatin alone or in 
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combination with PN517 reduced cell viability by more than 50%, but the PN517 
treatment alone was found to have little effect on viability. Statistical analysis using a 
One-Way ANOVA was performed as the data exhibited normality (Shapiro-Wilk’s and 
Kolmogorov-Smirnov, p > 0.05), and found that there was a significant difference 
between groups at 48 hours (F6,20 = 7.851, p = 0.001), and 72 hours (F6,20 = 90.573, p < 
0.001). Post-Hoc analysis found that all treatments at 48 hours were significantly 
different from control (p < 0.05) apart from aspirin and PN517 (p = 1), and at 72 hours, 
all treatments were significantly different from control (p < 0.05) apart from aspirin and 
PN517 (p = 1). Interestingly, while, the combination of PN517 with cisplatin was not 
significantly different from cisplatin alone, the combination of aspirin with cisplatin 
was significantly different from cisplatin alone (p < 0.05). 
 
A similar pattern of results was observed in the SVG-p12 cell line (Fig 3.8, 
panels B & D), although with smaller reductions in cell viability when compared to U-
87 MG cell line. After 48 hours of treatment, PN517 reduced cell viability to 80% of 
control while cisplatin on its own was the most potent treatment, reducing the viability 
to approximately 50% of control (Fig 3.8, panel B). The combination of PN517 with 
cisplatin reduced viability to 44% of control. Following 72 hours of treatment (Fig 3.8, 
panel D), similar results were observed with the PN517 combination treatment with 
cisplatin reducing cell viability to 62% of control, while PN517 and cisplatin on their 
own reduced viability to 64% and 50% of control. A One-Way ANOVA was performed 
as the data exhibited normality (Shapiro-Wilk’s and Kolmogorov-Smirnov, p > 0.05) 
and found a significant difference between groups at 48 hours (F6,20 = 9.949, p < 0.001), 
and 72 hours (F6,20 = 61.514, p < 0.001). Post-Hoc tests determined that all treatments at 
48 and 72 hours were significantly different from control (p < 0.05) apart from aspirin 
  
 
52 
 
and PN517 (p = 1). Again, however, the combination of PN517 with cisplatin was not 
significantly different from cisplatin alone. 
3.3 Cell Proliferation 
One factor which can affect cell viability is cell proliferation, so CFDA-SE 
staining was used to examine any changes following drug treatment. CFDA-SE enters 
the cells via diffusion through the plasma membrane. Once it enters the cell, the cellular 
esterases convert the CFDA-SE to CFSE which is fluorescent in nature. CFSE forms a 
covalent bond with the amine groups in proteins, thereby resulting in retention of the 
dye inside the cell. Following cell division, each daughter cell receives approximately 
half of the dye from the parent cell. Analysing the fluorescence intensity via the flow 
cytometer helps in determining the number of generations the cell has progressed 
through after the addition of the stain (Wang et al., 2005). 
 In the U-87 MG glioblastoma cell line (Fig 3.9), the biggest effect on 
proliferation rate was observed following treatment with cisplatin, with a rightward shift 
in the proliferation curve when compared to control. The affect was biggest at 24 and 48 
hours, with cells appearing to recover at 72 and 96 hours where fluorescence intensity 
approached that of control treatment. Neither treatment with aspirin, nor PN517 alone 
affected proliferation. Interestingly, the combination of either aspirin or PN517 with 
cisplatin reduced the effect of cisplatin on proliferation. When proliferation in the SVG-
p12 cell line was examined (Fig 3.10), none of the treatments, either mono or 
combination, had any effect on cell proliferation when compared to control.  
 
Sample results for the proliferation data are shown in figures 3.11 (U-87 MG) 
and 3.12 (SVG-p12), where a shift in peak to the left indicates cell proliferation, with 
each colour indicating a different timepoint of analysis. In the U-87 MG cell line (Fig 
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3.11), it can be clearly seen that compared to control (panel A), cisplatin treatment has 
reduced the leftward shift in the fluorescence peak (panel F). However, little difference 
is observed in the leftward shift of peaks compared to control for any of the drug 
treatments in the SVG-p12 cell line (Fig 3.12). 
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3.4 Apoptosis 
3.4.1 Annexin-V and Propidium Iodide 
Another factor which can affect cell viability is cell death, commonly as a result 
of apoptosis, so staining with annexin-V and propidium iodide was used to examine any 
changes following drug treatment for 24 and 48 hours. 
 
In the U-87 MG glioblastoma cell line, drug treatment induced apoptosis at both 
time points, with staining indicating both early (annexin-V alone) and late (annexin-V 
and PI) apoptotic populations, and a low level of necrosis (PI alone) (Fig 3.13). After 24 
hours of drug treatment, only 8 % of cells remained unstained following treatment with 
cisplatin (high), while 32 % were unstained after treatment with aspirin (Fig 3.14, 
panels A and B). The combination of PN517 with cisplatin (low or high) increased the 
proportion of late apoptotic cells when compared to cisplatin alone following 24 hours 
of treatment, while the levels of unstained (live) cells did not vary. Following 48 hours 
of treatment, a general trend towards a decrease in staining was observed (Fig 3.13, 
panels C and D). The combination of PN517 with cisplatin (high) resulted in the 
smallest proportion of living cells (19 % of control), while 56 % of cells remained 
unstained (live) following aspirin alone (panel D).  The combination of PN517 with 
cisplatin (high) showed the greatest induction of apoptosis with 81 % of cells in either 
the early or late phases. Cisplatin (high) along produced the largest necrotic population 
(3 % of control). 
 
Results for the SVG-p12 cell line showed lower levels of apoptosis (Fig 3.14), 
particularly at 48 hours, when compared to the U-87 MG cells. Following 24 hours of 
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incubation, treatment with aspirin alone resulted in the highest proportion of live cells, 
44 % of control (Fig 3.14, panel B), while less that 20 % of cells were living following 
treatment with the combination of PN517 and cisplatin (high). The same combination 
treatment also induced early apoptosis in the highest percentage of cells, 90 % of 
control, while aspirin had the least at 56 % (Fig 3.14, panels A and B). The combination 
of PN517 and cisplatin (high) also had the highest proportion of late-apoptotic cells, 52 
% of control, while cisplatin (low) had the lowest at 13 % of control. Little necrosis was 
observed with a maximum of 2 % being found in the mono-treatments (Fig 3.14, panel 
B). After 48 hours of drug treatment (Fig 3.14, panels C and D), an increase in the 
proportion of live cells was observed following most treatments, with 83 % of cells 
living following cisplatin (high) treatment. However, the combination of PN517 with 
cisplatin (high) resulted in the lowest proportion of living cells at only 5 % of control. In 
each case, the combination of PN517 with cisplatin (low or high) resulted in the largest 
populations of early and late apoptotic cells. The treatment with the highest proportion 
of necrotic cells was cisplatin (high) at 7 % of control.  
 
Representative dot plots for annexin-V and propidium iodide staining in the U-
87 MG and SVG-p12 cell lines following 24 and 48 hours of drug treatment are shown 
in figures 3.15 and 3.16 respectively.  The increase in annexin-V and propidium iodide 
staining following drug treatment in U-87 MG cells (panels B-D) and SVG-p12 cells 
(panels F-H) in comparison to their respective controls (panels A and E) can clearly be 
observed.  
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3.4.2 Caspase 8 and 9 Activation 
In order to examine the mechanism of apoptosis, the activation of caspase 8 
(extrinsic pathway) and caspase 9 (intrinsic pathway) was examined using the 
luminescent Caspase-glo
®
 assay, following 12, 24 and 48 hours of drug treatment (Fig 
3.17 and 3.18).  
 
After 12 hours of treatment, with the exception of cisplatin (low or high), all 
treatments increased caspase 8 activity when compared to control (Fig 3.17, panel A). 
The combination of PN517 and cisplatin (high) produced the largest increase in caspase 
8 activity, 191 % of control. Following 24 hours of treatment aspirin and its 
combination with cisplatin showed high caspase activity. However, cisplatin had not 
managed to induce any significant activity as compared to control. After 48 hours of 
drug treatment, cisplatin (low and high) induced caspase 8 activity when compared to 
control, but the combination of cisplatin with PN517 reduced caspase 8 activity when 
compared to cisplatin alone (Fig 3.17, panel E). Unusually, PN517 treatment alone 
actually reduced caspase 8 activity when compared to control. A One-Way ANOVA 
was performed as the data exhibited normality (Shapiro-Wilk’s and Kolmogorov-
Smirnov, p > 0.05), but no significant difference was found between groups at any time 
point (p > 0.05). 
 
In the SVG-p12 cell line, following 12 hours of drug treatment, no increase in 
caspase 8 activity was observed when compared to control (Fig 3.17, panel B), with all 
treatments showing a decreased compared to control. PN517 treatment resulted in the 
biggest decrease in activity, reducing it to 37 % of control. Following 24 hours of drug 
treatment, most treatments increased caspase 8 activity when compared to control with 
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the combination of cisplatin (low) and aspirin showing activity of 198 % of control (Fig 
3.17, panel D). Interestingly, aspirin treatment alone showed activity of 192 % of 
control, and the combination of PN517 with cisplatin (high) showed the lowest activity. 
However, following 48 hours of incubation, activity appeared to change significantly 
again, with cisplatin (low) showing the largest activation at only 126 % of control (Fig 
3.17, panel F). PN517 in combination with cisplatin (low), was shown to decrease 
activity to only 7% of the media control. A One-Way ANOVA was performed as the 
data exhibited normality (Shapiro-Wilk’s and Kolmogorov-Smirnov, p > 0.05) and a 
significant difference between groups was found at 12 hours (F8,27 = 4.790, p = 0.001), 
and 48 hours (F8,27 = 4.081, p < 0.001). Post-Hoc analysis found that at 12 hours PN517 
was significantly different from control (p < 0.05). 
 
In a similar manner, caspase 9 activation was examined following drug 
treatment for 12, 24 and 48 hours (Fig 3.18). In the U-87 MG cell line, as with caspase 
8, cisplatin alone did not increase caspase 9 activity following 12 hours of treatment  
(Fig 3.18, panel A). However, aspirin and PN517 alone and in combination with 
cisplatin did increase caspase 9 activity when compared to control. Following 24 hours 
of drug treatment, a very similar pattern was observed with little effect found following 
treatment with cisplatin (low or high), but both aspirin, PN517, and their combination 
with cisplatin increasing caspase 9 activity compared to control (Fig 3.18, panel C). 
Aspirin in combination with cisplatin (high) induced the highest caspase-9 activity at 
219 % of control. After 48 hours of incubation, cisplatin (low) did increase caspase 9 
activation to 356 % of control (Fig 3.18, panel E). A One-Way ANOVA was performed 
as the data exhibited normality (Shapiro-Wilk’s and Kolmogorov-Smirnov, p > 0.05), 
but no significant difference between groups was found at any time point (p > 0.05). 
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In the SVG-p12 cell line, following 12 hours of incubation none of the 
treatments had any effect on caspase 9 activity, with PN517 treatment resulting in 
activity of 56 % of control (Fig 3.18, panel B). A similar pattern was observed after 24 
hours with the only exception being aspirin in combination with cisplatin (low), 
increasing activity to 116 % of control (Fig 3.18, panel B). Even after 48 hours of 
treatment, no significant change in caspase-9 activity was observed (Fig 3.18, panel F). 
However, cisplatin (low) did increase activity to 136 % of control. A One-Way 
ANOVA was performed as the data exhibited normality (Shapiro-Wilk’s and 
Kolmogorov-Smirnov, p > 0.05), but no significant difference between groups was 
observed at any time point (p > 0.05). 
 
Given some of the unexpected results of the Caspase-glo
®
 assays, images of 
cells were taken to determine if any morphological changes consistent with apoptosis 
were observed. In comparison to control cells (Fig 3.19), it can clearly be seen that at 24 
and 48 hours (Fig 3.20 and 3.21 respectively), PN517 treatment resulted in a rounding 
of cells and also a decrease in cell density, changes consistent with apoptosis. These 
effects were observed in both the U-87 MG and SVG-p12 cell lines. 
 
3.4.3 Laser Scanning Confocal Microscopy 
In a similar manner, confocal microscopy was also used to qualitatively confirm 
the induction of apoptosis following drug treatment, using staining with annexin-V and 
propidium iodide. Annexin-V binding (green) indicates binding to the cell surface early 
apoptotic marker, phosphatidylcholine, and propidium iodide staining (red) of the 
nucleus indicates late apoptosis and a compromised cell membrane. 
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In the U-87 MG cell line (Fig 3.22), control treatment showed sparse staining 
with annexin-V, indicating early apoptosis in a few cells, but no late apoptosis was 
observed. Following 24 hours of drug treatment, aspirin treatment induced early 
apoptosis with a small population of late apoptosis, while PN517 treatment resulted in 
the induction of early apoptosis in most the cells and a larger proportion of late 
apoptosis when compared to aspirin treatment. In a similar fashion to PN517 treatment, 
cisplatin treatment induced early apoptosis in the majority of cells. The combination of 
cisplatin with PN517 or aspirin resulted in the induction of early apoptosis in all 
observed cells, and late apoptosis in a large proportion also.  
 
Treatment of the SVG-p12 cell line showed a similar pattern of staining with a 
small number of cells showing annexin-V staining in control, induction of early 
apoptosis in cells following aspirin, PN517 or cisplatin treatment alone, with a small 
proportion of late apoptotic cells. Again, combination treatments resulted in high 
intensity staining indicating induction of early apoptosis but little evidence of late stage 
apoptosis.  
 
3.5 Autophagy 
The potential involvement of autophagy in the reduction of cell viability 
following drug treatment was examined using the selective autophagy inhibitor, 3-
methylanadine (3-MA). Initial experiments examined the effect of 3-MA alone on cell 
viability (Fig 3.24). A concentration response assay found that concentrations below 
5mM did not affect cell viability, thus 0.5mM 3-MA was chosen as a co-treatment in 
further experiments. 
 
  
 
60 
 
A dose-dependent reduction in cell viability was observed following treatment 
with either PN517 or cisplatin following 24 and 48 hours of incubation in U-87 MG cell 
line (Fig 3.25), with IC50 values of 0.96mM & 0.58mM and 125µM & 10µM 
respectively.   Addition of 3-MA (0.5mM) did not significantly change the 
concentration response observed for either PN517 or cisplatin at either time point (p > 
0.05). Similar results were observed in the SVG-p12 cell line, with 3-MA treatment not 
significantly changing the concentration response to PN517 or cisplatin treatment 
following 24 or 48 hours of drug treatment. 
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Figure 3.1: Growth curve for U-87 MG and SVG-p12 cell lines. 
Following an initial seeding density of 20,000 cells per well, proliferation was 
determined by cell counting on nine subsequent days. U-87 MG and SVG-p12 cell lines 
demonstrated doubling times of approximately 2 and 3 days respectively. Data illustrate 
mean cell number ± SD generated from three independent experiments. 
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Figure 3.2: Effect of increasing cell number on fluorescence determined by 
PrestoBlue
® 
assay in U-87 MG and SVG-p12 cell lines. 
The relationship between fluorescence and U-87 MG (panel A) or SVG-p12 (panel B) 
cell number illustrated following 24 (closed circles) and 48 (closed triangles) hours of 
incubation. Data illustrate mean fluorescence ± SD generated from three independent 
experiments. 
 
0 2000 4000 6000 8000 10000
0
10000
20000
30000
Cell Number
F
lu
o
r
e
se
n
c
e
 (
6
1
2
 n
m
)
0 2000 4000 6000 8000 10000
0
10000
20000
30000
Cell Number
F
lu
o
r
e
se
n
c
e
 (
6
1
2
 n
m
)
A 
B 
  
 
63 
 
A      B 
-6 -5 -4 -3 -2
0
20
40
60
80
100
120
Log Concentration (M)
V
ia
b
il
it
y
 (
%
 o
f 
C
o
n
tr
o
l)
-6 -5 -4 -3 -2
0
20
40
60
80
100
120
Log Concentration (M)
V
ia
b
il
it
y
 (
%
 o
f 
C
o
n
tr
o
l)
 
C      D 
-6 -5 -4 -3 -2
0
20
40
60
80
100
120
Log Concentration (M)
V
ia
b
il
it
y
 (
%
 o
f 
C
o
n
tr
o
l)
-6 -5 -4 -3 -2
0
20
40
60
80
100
120
Log Concentration (M)
V
ia
b
il
it
y
 (
%
 o
f 
C
o
n
tr
o
l)
 
 
Figure 3.3: Data illustrating the effect of dose-dependent treatment of aspirin 
(closed circle) and cisplatin (closed square) on U87-MG and SVG-P12 cell lines. 
Cell viability was determined using PrestoBlue
®
 assay for cell viability. Panel A and C 
show the effect of the drugs on U87-MG cell line (1000cells/well) at 24 and 48 hours 
respectively. Panel B and D illustrate the effect of the drugs on SVG-P12 
(1000cells/well) at 24 and 48 hours respectively. The data represents mean ± SEM of 
three experiments. 
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Figure 3.4: Dose dependent effects of temozolomide (closed circle) and PN517 
(closed square) on cell viability in U87-MG and SVG-P12 over 24 and 48 hours. 
Data illustrating the effect of dose-dependent treatment of temozolomide (closed 
circles) and PN517 (closed squares) on U87-MG and SVG-P12 cell lines 
(1000cells/well). Cell viability was determined using PrestoBlue
®
 assay for cell 
viability. Panel A and C show the effect of the drugs on U87-MG cell lines at 24 and 48 
hours respectively. Panel B and D illustrate the effect of the drugs on SVG-P12 at 24 
and 48 hours respectively. The data represents mean ± SEM of three experiments. 
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 IC50 value  
 24 hours 48 hours 
Aspirin 3.2 mM 3.5 mM 
Cisplatin 100 µM 9 µM 
PN517 1.4 mM 1.9mM 
Table 3.1: IC50 values for U-87 MG cell line following 24 and 48 hours incubation 
with aspirin, cisplatin and PN517. 
 
 
 IC50 value  
 24 hours 48 hours 
Aspirin 3.9 mM 2.7 mM 
Cisplatin 8 µM 22 µM 
PN517 1.7 mM 1.8 mM 
Table 3.2: IC50 values for SVG-P12 cell line following 24 and 48 hours incubation 
with aspirin, cisplatin and PN517. 
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Figure 3.5: Cell viability following combination treatment of aspirin and PN517 
with cisplatin and of aspirin with PN517 in a time dependent manner in U87-MG 
cell line. 
Cell viability was determined using the PrestoBlue® viability assay following 2, 4, 8, 
12, 24 and 48 hours of incubation. Panels A, B, C, D, E and F represent cell viability at 
2, 4, 8, 12, 24 and 48 hours respectively. Data is a mean ± SEM of three experiments. 
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Figure 3.6: Cell viability following combination treatment of aspirin and PN517 
with cisplatin and of aspirin with PN517 in a time dependent manner in SVG-P12 
cell line. 
Cell viability was determined using the PrestoBlue® viability assay following 2, 4, 8, 
12, 24 and 48 hours of incubation. Panels A, B, C, D, E and F represent cell viability at 
2, 4, 8, 12, 24 and 48 hours respectively. Data is a mean ± SEM of three experiments. 
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Figure 3.7: Cell viability after staggered treatment of aspirin/PN517 followed by 
cisplatin. 
Cell viability was determined using PrestoBlue viability assay following 48 hours of 
incubation. Panel A illustrates data for U87-MG cell line while panel B indicates data 
for SVG-P12 cell line. Data is a mean ± SEM of three experiments. 
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Figure 3.8: Cell viability after prolonged treatment with aspirin/ analogue followed 
by cisplatin. 
Cell viability was determined using PrestoBlue viability assay. Panel A and C illustrate 
data for U87-MG cell line at 48 hours and 72 hours while panel B and D indicate data 
for SVG-P12 cell line at 48 and 72 hours respectively. Data is a mean ± SEM of three 
experiments 
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Figure 3.9: Cell proliferation following drug treatment in U87-MG cell line. 
The data illustrates the cell proliferation observed in U87-MG cell line 
(150,000cells/well) using CFDA-SE assay following drug treatment (0.1mM) over a 
period of 5 days. Panel A displays the effect of aspirin (closed square), PN517 (closed 
triangle), cisplatin (closed inverted triangle) and the combinations of aspirin-cisplatin 
(closed diamond) and PN517-cisplatin (open circle) along with the control (closed 
circle) on cell proliferation where a shift towards the right depicts reduction in 
proliferation. Panel B shows the effect of aspirin, cisplatin and their combination, panel 
C shows the effect of PN517, cisplatin and their combination treatment on proliferation.  
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Figure 3.10: Cell proliferation following drug treatment in SVG-P12 cell line. 
The data illustrates the cell proliferation observed in SVG-P12 cell line (150,000 
cells/well) using CFDA-SE assay following drug treatment (0.1mM) over a period of 5 
days. Panel A displays the effect of aspirin (closed square), PN517 (closed triangle), 
cisplatin (closed inverted triangle) and the combinations of aspirin-cisplatin (closed 
diamond) and PN517-cisplatin (open circle) along with the control (closed circle) on 
cell proliferation where a shift towards the right depicts reduction in proliferation. Panel 
B shows the effect of aspirin, cisplatin and their combination, panel C shows the effect 
of PN517, cisplatin and their combination treatment on proliferation.  
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Figure 3.11: Cell proliferation following drug treatment in U87-MG cell line.  
The data illustrates the effect ensuing drug treatment over a period of five days, a 
leftward shift indicating cell proliferation. Panel A depicts control treatment, where a 
shift towards the left can be observed. Panel B and C are for Aspirin and PN517 
treatments respectively, panel D shows effect following cisplatin treatment, where over 
lapping peaks suggest inhibition of proliferation. Panel E indicates aspirin-cisplatin 
combined treatment effects while panel F indicates effects following PN517-cisplatin 
combined treatment. 
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Figure 3.12: Cell proliferation following drug treatment in SVG-P12 cell line 
The data illustrates the effect ensuing drug treatment over a period of five days, a 
leftward shift indicating cell proliferation. Panel A depicts control treatment, where a 
shift towards the left can be observed. Panel B and C are for Aspirin and PN517 
treatments respectively, panel D shows effect following cisplatin treatment, where over 
lapping peaks suggest inhibition of proliferation. Panel E indicates aspirin-cisplatin 
combined treatment effects while panel F indicates effects following PN517-cisplatin 
combined treatment. 
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Figure 3.13: Apoptosis following drug treatment in U87-MG cell line. 
Data illustrates the apoptosis observed in U87-MG cell line with the help of Annexin-V 
and Propidium iodide (PI) staining. Panel A and B show the relative proportions of cell 
in healthy, early and late apoptotic or necrotic state following 24 hours of drug 
treatment. Panel C and D illustrate the same data as seen at 48 hours post-drug 
treatment. 
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Figure 3.14: Apoptosis following drug treatment in SVG-P12 cell line. 
Data illustrates the apoptosis observed in SVG-P12 cell line with the help of Annexin-V 
and Propidium iodide (PI) staining. Panel A and B show the relative proportions of cell 
in healthy (colourless), early (light grey) and late apoptotic (dark grey) or necrotic 
(black) state following 24 hours of drug treatment. Panel C and D illustrate the same 
data as seen at 48 hours post-drug treatment. 
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Figure 3.15: Dot-plots for Apoptosis assay following 24 hours of drug treatment in both the cell lines. 
Images obtained from the flow-cytometer following analysis of the apoptosis assay at 24 hours. Panels A,B,C,D are treatments for U87-
MG cell while panels E,F,G,H are for SVG-P12 cells The treatments are as follows: A & E) Control, B & F) Aspirin, C & G) PN517, D & 
H) PN517+Cisplatin-high. Quadrant 1 indicates necrotic cells; quadrant 2 indicates late apoptosis; quadrant 3 depicts live cells whereas 
quadrant 4 indicates early apoptosis. 
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Figure 3.16: Dot-plots for Apoptosis assay following 48 hours of drug treatment in both the cell lines. 
Images obtained from the flow-cytometer following analysis of the apoptosis assay at 48 hours. Panels A,B,C,D are treatments for U87-
MG cell while panels E,F,G,H are for SVG-P12 cells The treatments are as follows: A & E) Control, B & F) Aspirin, C & G) PN517, D & 
H) PN517+Cisplatin-high. Quadrant 1 indicates necrotic cells; quadrant 2 indicates late apoptosis; quadrant 3 depicts live cells whereas 
quadrant 4 indicates early apoptosis.  
  
 
78 
 
A      B 
    
C      D 
    
E      F 
    
Figure 3.17: Caspase-8 activity seen U87-MG and SVG-P12 cell lines. 
Data illustrates caspase-8 activity in both the cell lines following drug treatment. Panels 
A, C, and E show effects in U87-MG cell line following 12, 24 and 48 hours of 
incubation following drug treatment. Panels B, D and F show caspase-8 activity in 
SVG-P12 cells following same time points respectively.  Data are mean ± SEM of four 
experiments.  
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Figure 3.18: Caspase-9 activity seen U87-MG and SVG-P12 cell lines. 
Data illustrates caspase-9 activity in both cell lines following drug treatment. Panels A, 
C, and E show effects in U87-MG cell line following 12, 24 and 48 hours of incubation 
following drug treatment. Panels B, D and F show caspase-9 activity in SVG-P12 cells 
following same timepoints respectively.  Data are mean ± SEM of four experiments. 
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Figure 3.19: Cell images of control treatments in U87-MG and SVG-P12. 
Images show the effects of control (media) treatments on the cells prior to caspase 
analysis detected via Brightfield microscopy. Panels A and C show the effects at 24 
hours and 48 hours in U87-MG cells respectively. Panels B and D illustrate the effects 
seen at 24 and 48 hours for SVG-P12 cells.   
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Figure 3.20: Brightfield microscopy images following drug treatment in U87 and 
SVG cells at 24 hours.  
Images show the effect of drug treatment prior analysis of caspase activity at 24hours. 
Images A, C and E illustrate effect of PN517, cisplatin (high-dose) and PN517-cisplatin 
(high-dose) combination effects in U87-MC cells respectively. Images B, D and F show 
the effect of same treatments in SVG-P12 cells respectively. 
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Figure 3.21: Brightfield microscopy images following drug treatment in U87 and 
SVG cells at 48 hours. 
Images show the effect of drug treatment prior analysis of caspase activity at 48 hours. 
Images A, C and E illustrate effect of PN517, cisplatin (high-dose) and PN517-cisplatin 
(high-dose) combination effects in U87-MC cells respectively. Images B, D and F show 
the effect of same treatments in SVG-P12 cells respectively. 
U87-MG cells 
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Figure 3.22: Confocal images showing induction of apoptosis following drug treatment in both the cell lines. 
Panel A, B and C show the effects of drug treatment on apoptosis at 24 hours in U87-MG cells whereas D, E and F in SVG-P12 cells. The 
treatments are as follows: A & D) control; B & E) aspirin; C & F) PN517
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Figure 3.23: Confocal images showing induction of apoptosis following drug treatment in both the cell lines. 
Panel A, B and C show the effects of drug treatment on apoptosis at 24 hours in U87-MG cells whereas D, E and F in SVG-P12 cells. The 
treatments are as follows: A & D) cisplatin; B & E) aspirin+cisplatin; C & F) PN517+cisplatin
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Figure 3.24: 3-MA dose response curve for U87-MG and SVG-P12 cell lines at 24 
and 48 hours. 
Data illustrates the effects of autophagy inhibitor 3-MA on the cell viability. Panel A 
shows the effect of 3-MA by itself on cell viability. Panels B and D show the effect of 
the dose–dependent drug treatments with or without the inhibitor in U87-MG cells 
following drug treatment with PN517 (closed square) and cisplatin (open circle) after 24 
and 48 hours of incubation respectively. Panel C and E show the effects in SVG-P12 
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cells following 24 and 48 hours of incubation respectively. Individual drug treatments 
are shown as PN517 (closed circle) and cisplatin (closed diamond).  
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4 Discussion 
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The main aim of this study was to examine the effect of combined treatment 
involving standard chemotherapeutics and aspirin or its analogue PN517 on a 
glioblastoma cell line in vitro. It was hypothesised that the combined treatment would 
reduce cell viability and proliferation of U87-MG glioblastoma cell line to a greater 
extent than individual treatments. While variation was observed between assays, the cell 
viability results provide the first evidence that PN517 might have therapeutic potential 
for the treatment of glioma.  The remaining aims of the project focused on identifying 
the mechanisms involved in cell death following drug treatment of the U87-MG cell 
line. 
 
4.1 Growth Curve and PrestoBlue® Linearity 
As would be expected of a cancer cell line, the U87-MG cells demonstrated a 
higher rate of proliferation as compared to non-cancerous foetal SVG-P12 control cell 
line (Fig. 3.1) (Hanahan & Weinberg, 2011). The U87-MG cells doubled in number 
over forty eight hours after initial seeding and the trend continued till the eighth day 
demonstrating a log phase of expansion, after which a decline in proliferation rate was 
observed indicating a lag phase. The PrestoBlue
®
 assay uses the reducing nature of the 
cell environment as an indication of viability, but when measuring the response of a 
population of cells, the largest variable impacting response is the cell number 
(www.invitrogen.co.uk). The linearity assay established that over the period of 
incubation and with a two day doubling time, fluorescence was proportional to cell 
density (Fig. 3.2). Taken in combination, these results established that drug treatment 
after a twenty four hour incubation period following seeding of one thousand cells per 
well was appropriate for subsequent viability assays. 
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4.2 Cell Viability 
Aspirin demonstrated its cytotoxic effects by reducing the cell viability of both 
the U87-MG and SVG-P12 cell lines in a concentration dependent manner (Fig. 3.3), 
displaying similar efficacy to that found in previous studies (Hwang et al., 2004; Kim et 
al., 2009b; Deb et al., 2011). The IC50 value however, did not significantly change with 
either twenty-four or forty eight hours of treatment (Tables 3.1 & 3.2). A possible 
explanation for this result would be the metabolism of aspirin in vitro by cytochrome 
P450 enzymes.  
 
In vivo, low dose aspirin has a half-life of approximately four hours because 
following rapid de-acetylation to salicylic acid, aspirin is further metabolized by 
glucuronidation, hydroxylation, and glycine conjugation (Hutt et al., 1986; Takanashi et 
al., 2000). However, higher doses can extend the half-life to approximately thirty hours 
because the pathways concerned forming salicyluric acid and salicyl phenolic 
glucuronide products become saturated (Schror, 2009).  The cytochrome P450 enzymes, 
essential for detoxification of foreign chemicals, are a large family of fifty enzymes, six 
of which are responsible for the metabolism of ninety percent of drugs (Guengerich, 
2008). The enzymes are highly expressed in liver, but are also found in the small 
intestine, lungs, and at lower levels in most tissues throughout the body. The major 
cytochrome P450 involved in the metabolism of aspirin is CYP2C9 (Miners & Birkett, 
1998; Takanashi et al., 2000), which is polymorphic, and could also affect the 
metabolism of aspirin analogues. Importantly for this study, CYP2C9 is expressed in 
glioma, and its expression increases with grade, thus high expression is found in 
glioblastoma (Knüpfer et al., 2006). This provides a potential expression as to why the 
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IC50 remains constant for aspirin and its analogues, and may suggest a limiting factor 
for the use of aspirin or its analogues in the future treatment of GBM. 
PN517 is effectively two aspirin molecules joined by a double bond, a site 
which may represent a target for enzyme mediated hydrolysis. While it displayed 
greater efficacy than aspirin in both the U87-MG and SVG-P12 cell lines (Fig. 3.4), the 
metabolic mechanism already described could negatively impact its IC50 value, resulting 
in an underestimate of its potency. 
 
There are a number of mechanisms that could be involved in the effects of 
aspirin or its analogues on cell viability, including the Wnt/-catenin/TCF pathway.  
The signalling of the said pathway has been previously shown to be highly dysregulated 
in several cancers, with glioma being an example (Logan and Nusse, 2004; Cadigan and 
Peifer, 2009; Pu et al., 2009). The pathway is activated by the -catenin/TCF complex 
and serves as the main signalling node and activates several effectors like Stat3, AKT1 
and AKT2 (Chen et al., 2011; Huang et al., 2011; Yue et al., 2010). A study has shown 
that aspirin antagonizes the activity of the -catenin/TCF complex in U87-MG and 
A172 cell lines, thereby exerting its anti-neoplastic activity (Lan et al., 2011).  
 
Additionally, COX-2 has shown to be overexpressed in several glioblastoma cell 
lines, very notably in U87-MG which leads to excessive production of prostaglandins 
(Kardosh et al., 2011). COX-2 prostaglandins promote cell division, angiogenesis and 
metastasis while bringing about inhibition of apoptosis, which in turn leads to growth of 
the tumour (Grösch et al., 2006). This could be a possible explanation of the stronger 
inhibitory effect of aspirin and the PN517 analogue on the U87-MG cell line viability as 
compared to the SVG-P12 cell line (Tables 3.1 & 3.2). 
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The efficacy of aspirin and PN517 in vitro was compared to both cisplatin and 
temozolomide (Figs. 3.3 & 3.4), the leading drug in the treatment of glioblastoma 
multiforme (Zhang et al., 2012; Ding et al., 2012). TMZ is a prodrug which is 
converted into the active alkylating agent MTIC under physiological conditions 
(Friedman et al., 2000). However, temozolomide does not display similar effects in 
vitro due to its prodrug nature, instead displaying schedule-dependent activity. This 
could explain its weak effect against cell viability of both cell lines and failure in 
achieving an accurate IC50 value. 
 
Cisplatin is a potent anticancer chemotherapeutic due to targeting of multiple 
intracellular pathways to induce death in tumour cells (Rosenberg et al., 1975). In vitro, 
it displayed a time dependent efficacy, with a lower IC50 value following forty eight 
hours of treatment, an effect easily explained by its mechanism of action where it causes 
DNA damage by affecting its replication, ultimately inducing apoptosis (Florea & 
Büsselberg, 2011). Although cisplatin is cell cycle non-specific, during S-phase, 
toxicity is increased resulting in G2-phase arrest. Hence, as the cells replicate over time, 
a higher cytotoxic effect is seen, a mechanism that normally provides some selectivity 
over healthy cells when tumours are rapidly growing in comparison. 
 
Aspirin and PN517 in combination with cisplatin (high) significantly reduced 
the viability of the glioblastoma cells following twelve, twenty four and forty eight 
hours of incubation as compared to cisplatin on its own (Figs. 3.5 & 3.6). One possible 
explanation for this combined effect could be due to aspirin re-sensitizing the cisplatin-
induced resistance in tumour cells via inhibition of -catenin transactivation. It has been 
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noted that Akt phosphorylates Mdm2 subsequently down regulating p53 which causes 
drug resistance of cisplatin (Hung and Lau, 1999; Siddik, 2003). -catenin/TCF4 
transactivational complex serves as a central activating node for effectors such as Akt 
and Stat3 (Shi et al., 2013). As mentioned above, aspirin has shown to inhibit the effect 
of the -catenin/TCF4 complex in U87-MG cells and could thereby desensitize the cells 
to the cisplatin resistance induced by high dose cisplatin. It was also noted that 
following twenty four and forty eight hours of incubation of the glioblastoma cells with 
PN517 and cisplatin (low) caused a significant reduction in cell viability when 
compared to cisplatin (low) alone(Fig 3.5, panels E and F, Fig 3.7). This indicates that 
PN517 is augmenting the effect of cisplatin and a lower dose of cisplatin when 
combined with aspirin analogue can cause higher level of cytotoxic effect.  
 
These combination effects are significant if they can be reproduced in vivo, as 
lowering the dose of a highly toxic chemotherapeutic drug such as cisplatin, should 
significantly improve its side effect profile, while still producing similar treatment 
efficacy due to the addition of the second chemotherapeutic agent. Importantly, the side 
effect profile of aspirin is typically very good, and as previously mentioned the positive 
effects of aspirin on cancer outweigh the more serious side effects such as increased 
bleeding (Rothwell et al., 2012a). Given the high structural similarity to aspirin, it could 
be predicted that PN517 might have a similar side effect profile, while producing 
increased therapeutic efficacy. 
 
The study also found that prolonged treatment with aspirin followed by cisplatin 
significantly decreased cell viability in the U87-MG glioblastoma cell line when 
compared to cisplatin alone (Fig. 3.8). This could be due to aspirin mediated inhibition 
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of molecules central to regulation of cell cycle, cell survival and apoptosis. Kumar and 
Singh (2012) have shown that pre-treatment with aspirin in a T-cell lymphoma murine 
model, decreases the expression of several regulatory molecules such as Bcl-2, cyclin D 
and cyclin B1, changes which would  leave the cells susceptible to damage by an added 
dose of cisplatin. The study also found the p53 levels to be decreased in cells pre-treated 
with aspirin and subsequently treated with cisplatin, providing a simple explanation for 
the results obtained in the multiple-treatment assay. Unfortunately, no significant results 
were obtained in the staggered treatment of cisplatin followed by aspirin and PN517 
(Fig. 3.7). This could possibly be due to the cells recovering following the individual 
treatment, and again be linked to drug metabolism, emphasizing that a concomitant 
treatment is essential for combined efficacy. 
 
4.3 Cell Proliferation 
No significant effect was produced by either aspirin or PN517 alone on the cell 
proliferation of both the cell lines (Fig. 3.9-3.12), a result that might be due to the low 
concentration (100 M) of each drug in the assay. While it was previously reported that 
treatment using relatively low concentrations of aspirin, less than 500 M, doesn’t 
affect the cell growth of glioblastoma cells in a significant way (Amin et al., 2003), this 
concentration was chosen as one which was not going to significantly affect 
glioblastoma cell viability and prevent any independent measurement of proliferation. 
Low concentration cisplatin (10 µM) however, had a significant inhibitory effect on the 
cell proliferation over twenty four and forty eight hours, an effect that appeared to be 
overcome with further incubation at seventy two and ninety six hours. This effect was 
quite expected as already explained, the mechanism of action of cisplatin involves the 
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impedance of cell cycle and DNA replication (Siddik, 2003).  The combination of either 
aspirin or PN517 with cisplatin did not significantly affect proliferation when compared 
to cisplatin treatment alone, a result that was not unexpected given the lack of efficacy 
of the aspirin and analogue treatments on their own. However, although there wasn’t 
any combined effect, no antagonism was observed which implicates that low dose of 
aspirin with cisplatin could be of beneficial use. 
 
4.4 Apoptosis and Autophagy 
The high percentage of early as well as late apoptotic cells following drug 
treatment show that PN517 and aspirin reduce cell viability in glioblastoma cells via 
induction of apoptosis (Fig. 3.13-3.16). Cisplatin (high) combined with either aspirin or 
PN517 had a significant effect on apoptosis when compared to cisplatin alone, an effect 
maintained over twenty four and forty eight hours. Interestingly though, in all the other 
treatments, the apoptotic cell population was reduced at forty eight hours, suggesting 
that the cells were recovering. This could suggest that while a monotherapy would 
require daily dosing to maintain efficacy, a combination treatment might have a greater 
treatment interval. Combined with the lower doses of each individual drug in 
combination, this decreased treatment frequency might also improve the side effect 
profile of the chemotherapy. A further important result, was that apoptosis in the SVG-
P12 control cell line was lower than that in the GBM cell line, indicating that the 
combined therapy produced less damage to normal cells in terms of apoptosis, which 
could be of clinical importance. 
 
Results from the confocal microscopy provided morphological and 
immunofluorescent evidence of apoptosis induction following drug treatment. The 
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rounding of cells observed following treatment with PN517 on its own or in 
combination with cisplatin proved that it had caused permanent damage to the cells 
(Fig. 3.22 & 3.23) (Purow et al., 2005). The red staining, as a result of propidium iodide 
nuclear binding, confirmed late apoptosis with compromised cell membrane, and 
scattered nuclear fragments. In comparison to individual treatments, the combination of 
PN517 and cisplatin resulted in almost all observable cells demonstrating binding of 
annexin-V, thus indicating early apoptosis, and a significant proportion with propidium 
iodide staining, suggesting late apoptosis. The patterns from SVG-P12 cell treatments 
showed a similar pattern however, with lower proportion of late apoptotic cells. 
 
Apoptosis is associated with elevated levels of intra-cellular mediators such 
caspase-8 and caspase-9 (Chandra et al., 2002). The two major pathways of apoptosis, 
extrinsic and intrinsic pathways involve activation of caspase-8 and caspase-9 
respectively. Cisplatin treatment induces apoptosis independent of caspase-8, 9 which 
can be seen from the low and constant activity of both following high and low 
concentration treatments of the drug (Fig. 3.17-3.21).  Aspirin and PN517 showed 
similar effects on caspase activity in the glioblastoma cell line which seemed to 
decrease over time which suggested their involvement in induction of apoptosis. 
However, PN517 showed extremely low caspase activity in SVG-P12 cells suggesting a 
different pathway of apoptosis. In fact, the activity was 4 times lower than the activity 
seen in control treatments, suggesting inhibition of caspase activation by the drug. The 
combined drug treatments showed similar caspase 8 and 9 activity as seen in either 
aspirin alone or PN517 which was as expected due to low activity displayed by 
cisplatin, which didn’t change over time.  
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Following the caspase activation results, it was decided to examine the potential 
role of autophagy following drug treatment. The selective autophagy inhibitor, 3-
methyladenine, which inhibits activation of phosphatidylinositol 3-kinase/mammalian 
target of rapamycin (PI3K/mTOR) pathway, was used at a concentration which did not 
itself reduce cell viability (Glick et al., 2010). While these provisional results might 
suggest that neither PN517 nor cisplatin involve autophagy in their mechanism of 
reducing cell viability, no positive control was utilised to confirm either autophagy 
induction, or its inhibition by 3-MA (Fig. 3.24). Hence, the results have to be treated 
with caution. 
 
4.5 Conclusion 
The results of this study have demonstrated that PN517 or aspirin potentiate the 
effect of cisplatin in reducing viability and inducing apoptosis in the U87-MG 
glioblastoma cell line. This study provides the first evidence that the combination of a 
platinum based chemotherapeutic with aspirin or an aspirin analogue could be of 
therapeutic potential for the future treatment of glioblastoma multiforme. 
 
4.6 Future Work 
Further tests need to be performed to confirm the mechanism of induction of 
apoptosis and verify the involvement of different proteins. Substrates such as PARP or 
phosphorylated histones can be detected via immunohistochemistry. Western blots can 
be used to detect caspase activation.  
High pressure liquid chromatography could be used to confirm the metabolism 
of aspirin. The direct quantitation of aspirin or its metabolites salicylic acid, salicyluric 
  
 
97 
 
acid, gentsic acid can also be achieved via LC-MS/MS. The levels of CYP 450 enzymes 
could be determined in both U87-MG and SVG-P12 cell lines by western blotting in 
addition to activity assays. 
The involvement of -catenin pathway needs to be examined. This could be 
achieved by evaluating the activity of the b-catenin/TCF4 transcriptional complex using 
luciferase reporter constructs based assays.  
Although the results indicate the absence of autophagy, the lack of positive 
control could have led to generation of false-negative results. To overcome this, the 
experiments should be repeated using a positive control such as rapamycin. Other 
compounds testing involvement of autophagy can be utilised such as 
monodansylcadaverine (MDC), which accumulates in the autophagic vacuoles. It is an 
auto-fluorescent compound which can be visualised using confocal-laser scanning and 
autophagy is measured as the proportion of stained vacuoles. 
Better drug delivery methods could be used for dual-drug delivery which might 
include carriers such as microspheres or nano-particles. This approach could help to 
achieve higher concentrations of the drug in a tumour environment with reduced 
toxicity and side effects. Recent findings suggest that combining both the drugs to 
develop a prodrug can be highly beneficial. It can help in overcoming the cisplatin 
resistance and improve the cytotoxicity of the prodrug by altering the cellular uptake 
pathways (Cheng et al., 2014; Pathak et al., 2014) 
 Ultimately, the efficacy of combination treatments would need to be 
confirmed using both primacy glioblastoma cultures and also testing in vivo. The best 
available in vivo model would involve the induction of intracranial tumours in nude 
mice using both established cell lines and primary cells. This would allow for the 
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peripheral delivery of the combination therapy, establishing both efficacy and blood 
brain barrier penetration in a single model.  
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